1. Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation of the airways and is one of the major causes of death in the elderly. COPD leads to development of airflow limitation as evident by decreased forced expiratory volume in one second (FEV₁) and reduction in the percentage of FEV₁/ vital capacity. Standardised spirometric tests showing the presence of airflow obstruction are used in clinical diagnosis and more recently the use of high resolution CT scanning has been employed to detect early emphysematous changes which may be present prior to severe airflow obstruction (Figure 1).

In the lungs of patients with COPD elevated levels of pro-inflammatory cytokines such as interleukin (IL)-8, leukotriene-B₄ (LTB₄) and tumour necrosis factor-α (TNFα) have been recorded which can act as neutrophil chemoattractants. Once recruited to the airways, neutrophils are activated and release various compounds including reactive oxygen species, proteases and cationic proteins in order to clear infections. When released in excessive amounts, however, these molecules can cause extensive damage to the respiratory epithelium resulting in yet more pro-inflammatory cytokine release and further neutrophil influx, thereby creating a cycle of inflammation.

It is now clear that neutrophil serine proteases, including neutrophil elastase (NE), proteinase 3 (PR3) and cathepsin G (CathG) are major pathogenic determinants in chronic airway inflammatory disorders. Moreover, accumulating evidence indicates that the expression of matrix metalloproteases (MMPs) is dysregulated in COPD and these proteins are involved in small airway remodelling. Increased levels of both MMPs and serine...
proteases can participate in proteolytic attack on the alveolar wall matrix and, as a consequence the lung extracellular matrix is damaged, resulting in obstruction of small airways and development of emphysema.

Due to their implication in the pathology of COPD airways disease both MMPs and serine proteases have been in focus for drug-development efforts over the last two decades. Such concepts are further reinforced by scientific findings indicating that a variety of broad spectrum serine protease and MMP inhibitors significantly ameliorate emphysema in experimental animal models of COPD. To this end, in recent years continued efforts to identify and optimize novel mechanism-based inhibitors have led to a number of new inhibitors being reported. For example three natural protease inhibitors, secretory leucocyte protease inhibitor (SLPI), elafin and alpha-1 antitrypsin (AAT), have therapeutic potential for reducing the protease-induced inflammatory response and show promising potency and selectivity profiles. Other therapy options for the modulation of inflammation associated with excessive protease activity is the use of recombinant, synthetic or semi synthetic protease inhibitors. In this chapter we aim to describe the clinical and scientific evidence for the involvement of proteases and their proposed mode of action in COPD development and progression. Potential intervention with natural or synthetic inhibitors in the management of emphysematous symptoms associated with COPD will be reviewed in this chapter.

![Figure 1. Chest high resolution CT scan of COPD. A) A single slice from a high resolution CT (HRCT) scan of thorax demonstrating normal healthy lung parenchyma. B) A single HRCT thorax image of the upper lobes demonstrating loss of lung density in keeping with emphysematous change. C) Severe emphysema of the upper lobes showing markedly reduced lung density and bullous disease present (indicated by the arrow).](image)

### 2. The role of proteases in COPD

There are several classes of proteases and these include serine-, cysteine-, aspartate-, threonine-proteases and metalloproteases. For the purpose of this chapter we will focus on proteases which have been implicated in the pathogenesis of COPD and discuss particularly serine proteases and metalloproteases including NE, PR3, cathepsins and matrix metalloproteases.
2.1. Serine proteases

Serine proteases are a class of proteases which are involved in various physiological and pathological processes throughout the body and universally contain a serine as the amino acid at the active site of the enzyme [1]. Serine proteases include NE, CathG and PR3. They are primarily inactivated by serine protease inhibitors, the archetypal member of this family being AAT [2]. The main model for the protease-antiprotease imbalance is AAT deficiency, thus providing us with an insight into the importance of proteases in the development of emphysema [3, 4].

NE, PR3 and CathG are produced during neutrophil development in the bone marrow and are stored in the azurophilic (primary) granules of neutrophils [5]. These serine proteases are found in high concentrations in airway secretions of patients with inflammatory lung conditions [6, 7] and are seen in the circulating plasma of patients with severe sepsis and acute respiratory distress syndrome [8]. They have effects upon a broad range of extracellular matrix proteins including elastin, collagens, fibronectin, proteoglycans and laminin [9, 10]. Apart from AAT deficiency a large number of experimental animal studies also support the role of the protease/antiprotease imbalance in the pathogenesis of COPD, including the involvement of NE and PR3 in the development of emphysema [11, 12].

2.1.1. The serine protease neutrophil elastase

NE is a single polypeptide glycoprotein comprising 218 amino acids and is quite homologous with other serine proteases including PR3 and CathG [13]. NE is stored in the primary granules of neutrophils and when neutrophils are activated or primed by cytokines, it is released from the cell to the extracellular environment and may also rebinding and become expressed on the cell surface [14]. The activity of NE is primarily inhibited and regulated by AAT [2, 15] but other inhibitors of NE have been reported including monocyte neutrophil elastase inhibitor (MNEI/Serpin B1) [16], elafin [17, 18] and SLPI [19, 20]. Of interest, the converse has also been shown whereby NE has been shown to inactivate and cleave SLPI. [21]

Smoking may lead to an imbalance between proteases and antiproteases through the reduction of the functional activity of AAT in the lung and also as described earlier by increasing the number of proteases produced hence increasing the proportion of elastolysis in the lung. Moreover, cigarette smoke has been reported to inhibit the anti-NE activity of AAT in bronchoalveolar lavage (BAL) fluid of smokers compared to healthy non-smoking control subjects [22, 23], however some studies have argued against this point [24, 25]. Cigarette smoke has also been shown to induce the release of NE in BAL fluid [26] and also to increase the circulating NE levels seen in plasma [27]. This implicates NE in the pathogenesis of emphysema and studies in BAL from COPD patients demonstrated a direct correlation between the NE burden in BAL and the degree of emphysema seen on CT scans. Further to this, results showed an inverse relationship between the anti-elastase activity in the BAL of COPD patients and the degree of emphysema and diffusing capacity, supporting the protease-antiprotease imbalance theory of emphysema [28].
Further studies on the presence of NE in the airways have shown that NE can cleave a number of epithelial cell surface receptors [29], cell activators and signalling cytokines [30] thereby potentially orchestrating the airway inflammatory milieu. Moreover, data have shown that alveolar macrophages may bind and internalise NE [31] and a later study has reported increased levels of NE in alveolar macrophages of patients with emphysema, providing further evidence of the increased protease burden [32]. NE has also been demonstrated using immunohistochemistry to be localised to the elastin fibres in the lung parenchyma of patients with emphysema [33]. The theory of NE induced emphysema has been supported not only from human studies but excellent animal models. Indeed, tracheal instillation of NE has been shown to induce the infiltration of neutrophils into the lung and cause emphysema in experimental models [11, 34].

Apart from the well-known role of NE as a protease in the protease/antiprotease imbalance in emphysema it exerts additional effects which contribute to the pathogenesis of COPD. For example NE exposure has been shown to significantly increase macrophage production of cathepsin B and latent and active MMP-2 [35], whilst the addition of AAT to BAL fluid greatly reduced NE-induced cathepsin B and MMP-2 expression in macrophages in vitro [36]. Additionally, NE is involved in the hypersecretion of mucus seen in COPD and is also a secretagogue, inducing the submucosal gland cells and goblet cells to secrete mucus [37-39]. NE has been shown to induce the expression of MUC5AC at the gene level in epithelial cells and hence increase the production of mucin in the airway. This mechanism has been shown to be dependent on the presence of reaction oxygen species, linking the role of NE inducing mucus hypersecretion to smoking [40, 41]. Moreover, not only does NE increase the amount of mucus produced in the lung but it also interrupts the mucociliary clearance mechanism by decreasing the ciliary beat frequency of bronchial epithelial cells [42].

The importance of the immune system and the inflammatory process in the pathogenesis of COPD is becoming more apparent and NE is involved in several of these immune mechanisms. NE can induce the expression of IL-8 in bronchial epithelial cells via TLR-4, subsequently leading to neutrophil chemotaxis and increasing the inflammatory burden in the lung [43, 44]. NE also plays an important role in neutrophil migration both through the cleavage of fibrin [45] and through the chemo-attractant properties of NE complexed with AAT [46]. The immune function can be further affected by NE through the cleavage of CD4 and CD8 glycoproteins from the surface of T-cells, thus impairing the function of T-cells and contributing to the inflammation seen in COPD [47]. Moreover, NE up-regulates the expression of TGF-β1 in smooth airway muscle via the NFκB pathway and this may further contribute to the airflow limitation seen in COPD [48]. Additionally, NE plays a role in the apoptosis seen in the pathogenesis of emphysematous lesions. Accordingly NE has been demonstrated to induce endothelial cell apoptosis [49], cytolysis of epithelial cells [42, 50] and cleaves the hydrophobic phospholipid substrate phosphatidylserine receptor on macrophages, which subsequently impairs the ability of macrophages to clear apoptotic cells [51]. Collectively, these documented reports demonstrate that NE is an integral enzyme involved in the pathogenesis of COPD and emphysema and is a key target for therapeutic intervention.
2.1.2. Neutrophil derived proteinase 3

PR3 is the most abundant serine protease found in the neutrophil [52] and consequently more PR3 than NE is released by the neutrophil during the phagocytosis process [53]. Similar to NE, following activation of neutrophils by inflammatory cytokines, PR3 can be expressed on the surface of neutrophils [52] and AAT potently inhibits PR3 in the circulation [2, 54]. In contrast to AAT, SLPI has no effect upon PR3 and in fact PR3 is capable of degrading SLPI, thereby enhancing the activities of NE and other serine proteases [55].

Animal studies have demonstrated that PR3 plays a role in the development of emphysema, with studies showing that instillation of PR3 intra-tracheally leads to emphysematous lung disease in hamsters [12]. PR3 is found in the sputum of both stable COPD patients and AAT deficient individuals and increases at times of pulmonary exacerbations. Elevated PR3 levels correlate with an increase in neutrophilic burden [56]. However, its elastolytic rate is relatively low compared to NE, suggesting possibly a more minor role in the pathogenesis of emphysema [57]. Studies have also shown that PR3 maintains pro-inflammatory properties, possessing the ability to activate TNFα and IL-1β [58]. PR3 also has a strong effect on promoting the secretion of mucus in the airways [59] and can lead to cell apoptosis in the lung [49, 60].

2.1.3. Cathepsin G and other cathepsins

Not all cathepsins are serine proteases and in fact include aspartate and cysteine proteases. In this section we will discuss CathG, a serine protease related to NE and PR3 and briefly discuss other cathepsins and their role in COPD. Of major importance, increased levels of cathepsins have been demonstrated in BAL fluid of emphysema patients and therefore may play a role in the pathogenesis of the condition [61].

CathG is a serine protease and is stored in the primary granules of neutrophils. Upon release, activity of this protease is under the regulation of AAT and SLPI [19]. Increased levels of cathepsins can be seen in the BAL fluid of patients with emphysema [61] but unlike NE and PR3, in vivo animal studies have not demonstrated the same effect of CathG in inducing emphysema [62]. Similar to the other serine proteases however, CathG can induce secretion of mucus, hence adding to the airflow limitation and symptoms found in COPD [37]. Moreover, CathG can impair T-cell function by cleaving trans-membrane glycoprotein co-receptors on the cell surface in a similar fashion to NE [47].

Increased levels and activity of cathepsin L and cathepsin S have been shown in alveolar macrophages of smokers [63, 64]. The expression of cathepsin S is induced by INF-γ and this occurs in multiple cell types including smooth muscle cells. Subsequently, it has been shown that over-expression of IFN-γ can increase the expression of cathepsin B, D, L and S [65]. Moreover, in murine investigational studies cysteine-protease inhibitors markedly reduced the amount of airway inflammation and emphysema associated with over expression of cathepsins B, H, K, L and S [66]. In addition, bacterial killing by the antimicrobial peptide LL-37 and by human beta-defensins is inhibited due to proteolytic degradation by cathepsin D [67] and inactivation by the cysteine proteases cathepsins B, L, and S, respectively [68]. Although there is far less evidence and reported studies on cathepsins they most likely play a contribu-
tory role to the pathogenesis of emphysema and should also be considered as possible therapeutic targets in the future.

3. Matrix metalloproteases in COPD

MMPs are proteolytic enzymes which degrade components of the lung matrix, including collagens and elastins. This occurs both under normal physiological conditions and during abnormal pathological processes. MMPs are secreted as pro-enzymes and are activated by proteolytic conversion and have a close relationship with cytokines and growth factors [69, 70]. MMPs have both collagenase and elastase activity and account for 50% of the elastolytic activity of BAL fluid in smokers [71]. Indeed, MMPs account for the majority of the elastolytic activity of macrophages in COPD patients [72] and are counteracted by tissue inhibitors of matrix metalloproteases known as TIMPs. Additionally, MMPs do not only demonstrate degrading properties but also are pro-inflammatory in nature, with liberated matrix fragments possessing pro-inflammatory and monocytic chemotactic properties [73, 74].

3.1. Macrophage derived matrix metalloprotease-12

MMP-12, also known as macrophage-metalloelastase, is perhaps the most studied and best understood MMP in emphysema and COPD and numerous animal models have demonstrated its role in lung disease. It is involved directly in matrix degradation and is also a pro-inflammatory peptide. A recombinant form of human MMP-12 has been used to demonstrate the direct role that MMP-12 plays in the inflammatory process in the airways of mice [75]. This recombinant form of MMP-12 caused an increase in neutrophils and in macrophages accompanied by increased levels of pro-inflammatory cytokines and MMPs. Human studies have reported that the number of alveolar macrophages in BAL fluid expressing MMP-12 was higher in COPD patients than in controls [76]. MMP-12 can also be produced by bronchial epithelial cells [77] and is expressed by airway smooth muscle [78]. Cigarette smoke has been repeatedly shown to up-regulate both the release and production of MMP-12 [79]. How this occurs is complex in nature and likely through several mechanisms. For example, upon exposure to smoke, proteins including plasminogen and prothrombin are released into the alveolar space where they are converted to plasmin and thrombin, both of which are serine proteases. Their action upon proteinase activated receptor-1 (PAR-1) subsequently leads to the secretion and activation of MMP-12 [80, 81]. A second mechanism by which smoke may activate MMP-12 has been shown in mice where it was shown to up-regulate GM-CSF production which in turn controls MMP-12 release [82]. Moreover, the gene expression of MMP-12 in epithelial cells is affected by reactive oxygen species [83] and in murine studies a direct link between MMP-12 and cigarette smoke induced airway inflammation has been demonstrated [84-86]. Moreover, in MMP-12 knockout mice a marked reduction in monocyte recruitment and in IL-13 and IFN-γ induced emphysema has been demonstrated, implicating the importance of MMP-12 in the inflammatory response seen in COPD [65, 66]. How MMP-12 exerts this inflammatory effect is multifactorial. One reported mechanism involves the pro-
inflammatory action of MMP-12 through the release and activation of TNFα [87]. Secondly, MMP-12 has also been shown to possess the ability to induce the production and release of IL-8 via the EGFR pathway in epithelial cells [88]. The importance of MMP-12 in inducing airway inflammation is further supported by the use of MMP-12 inhibitors which were shown to ameliorate emphysema in experimental animals [89] and to lower both the concentration of immune cells in BAL fluid, and to affect inflammation [90]. MMP-12 also impacts upon the activity of other proteases, especially neutrophil derived enzymes including NE, PR3 and cathepsins, and can degrade AAT hence up-regulating the activity of these serine proteases [91].

Despite convincing evidence provided by experimental models and compelling data showing an association between MMP-12 and emphysema, the data from human studies is conflicting and not as clear cut. A number of studies have suggested increased expression of MMP-12 in alveolar macrophages and increased MMP-12 protein in sputum of COPD individuals compared to healthy controls [76, 92, 93] while others have shown no difference [94-96]. Thus further studies on MMP-12 are essential to confirm the role of this matrix metalloprotease in inflammation and tissues destruction associated with COPD.

3.2. Neutrophil released matrix metalloprotease-9

The next most studied and understood MMP in COPD is MMP-9. Also known as gelatinase-B and similarly to other matrix metalloproteases MMP-9 has multiple substrates including collagens IV, V, VII, X and XI as well as elastin, gelatin, pro-MMP9 and pro-MMP13. MMP-9 issecreted by bronchial epithelial cells, mast cells, neutrophils, eosinophils and alveolar macrophages in response to TGFβ, IL-13 and IL-8 [79].

Increased levels of MMP-9 have been demonstrated in smokers with and without airflow obstruction [97, 98] and a correlation between the levels of MMP-9 in sputum and the extent of airflow obstruction and symptoms in COPD has been reported [99]. There are also increased levels of MMP-9 in AAT deficient individuals, where levels correlated with clinical parameters including FEV1, DLCO, lung density and exacerbation frequency [98, 100]. Elevated levels of MMP-9 in COPD individuals have been demonstrated to correlate to the number of neutrophils, implicating MMP-9 in the inflammatory burden in COPD [98, 101]. Moreover, polymorphism in the promoter region of the human MMP-9 gene has been shown associated with emphysema in 2 separate Japanese cohorts [102, 103] and with COPD in a Chinese population [104].

In support of a role for the involvement of MMP-9 in COPD, ex vivo studies have shown that alveolar macrophages from BAL fluid in emphysema patients demonstrate increased expression of MMP-9 and MMP-1 compared to control subjects [95]. This is also true for smokers with and without COPD where there is increased expression of MMP-9 on alveolar macrophages compared to healthy controls [105, 106]. In a study comparing COPD patients to smokers with no evidence of airflow obstruction, alveolar macrophages from COPD individuals released increased levels of MMP-9 and in vitro the stimulation of these cells by IL-1β, lipopolysaccharides (LPS) and cigarette smoke increased the secretion of MMP-9 [106].
Consequently, emphysematous lung tissue has been shown to contain higher levels of MMP-9 compared to disease free tissue [107, 108].

Other studies of interest that provide evidence for the involvement of MMP-9 in the inflammatory process associated with COPD include data that demonstrate that MMP-9 possesses levels of TACE (TNFα converting enzyme) like activity and mediates acute cigarette smoke-induced inflammation via TNFα release [87]. MMP-9 may also be involved in the link between destruction of alveolar tissue and fibrotic proliferation observed in emphysema, potentially mediated by proteolytic cleavage of latent TGF-binding-protein-1 with subsequent release of TGFβ-1, possibly linking elastolysis and fibrosis [109, 110]. Interestingly, MMP-9 may be activated by NE via cleavage of pro-MMP-9 to active MMP-9 [111]. Moreover, NE has been shown to degrade TIMP-1 thereby leading to enhanced MMP-9 activity [112], implicating both NE and MMP-9 in the pathogenesis of COPD. Finally, a role for MMP-9 in mucus hypersecretion in COPD patients has been suggested, as MMP-9 activates epidermal growth factor which in turn increases the expression of MUC5AC production hence leading to increased mucus secretion [113, 114].

3.3. Matrix metalloprotease-1 and other matrix-metalloproteases

MMP-1, also known as interstitial collagenase-1, is active against multiple collagens including collagen I, II, III and VII, gelatin and pro-MMP9 and over-expression in mice has been associated with development of emphysema [115]. Loss of collagen type II leads to an increase in lung compliance and hence the development of emphysema [116]. In humans, BAL fluid from emphysema patients has increased MMP-1 expression compared to healthy controls [117] and increased expression of MMP1 was reported in the lungs of patients with emphysema [94]. This expression was localised to type II epithelial cells but not alveolar macrophages. MMP-1 is also expressed by airway smooth muscle [118] and the production of MMP-1 is driven by the MAPK pathway and also by hydrogen peroxide, an important pathogenic component of cigarette smoke [119]. In mouse models, MMP-1 has been shown to contribute to alveolar destruction leading to emphysema development [120, 121]. Similar to MMP-9, MMP-1 also possesses levels of TACE like activity which may contribute to the inflammation seen in COPD [87].

MMP-2 which is also known as gelatinase-A has activity against collagens I-V, VII, X, XI and XIV as well as elastin, fibronectin and gelatin. Increased levels of MMP-2 have been demonstrated in COPD lungs [107, 108] and also in experimental mice exposed to cigarette smoke [122]. Interestingly, in guinea pigs exposed to wood-smoke increased expression of MMP2 was recorded, possibly providing an insight into the pathogenesis of emphysema in individuals not exposed to cigarette smoke [123]. Moreover, increased levels of both MMP-8 and MMP-10 are seen in sputum of COPD patients and have been shown to correlate with airflow obstruction [97, 124], with increased levels of MMP-8 recorded at the time of acute pulmonary exacerbation [125]. Finally, MMP-12 is up-regulated in mice exposed to cigarette smoke [126] and elevated levels of MMP-13 are seen in individuals with emphysema [127].

Collectively, this information on MMPs contributes to the protease/antiprotease theory in COPD pathogenesis and provides targets that may be investigated when developing future
therapeutic strategies. MMPs play a mixed role in COPD and are involved in the proteolytic destruction of lung tissue and possess a close relationship to neutrophil derived serine proteases. These latter processes are intertwined and hence targeting certain elements of protease induced inflammatory processes may provide encouraging and exciting therapeutic options.

4. Approaches to treatment

Current therapies for the treatment of COPD are similar between the non-genetically inherited form of the lung disease and COPD as a result of AAT deficiency, and are in line with the American Thoracic Society/European Respiratory Society published guidelines [128]. Of particular importance is the cessation of smoking for individuals diagnosed with the disorder, as smoking aggravates the condition and is a predominant prognostic factor for the outcome of COPD patients. Therapeutic strategies aimed at the protease-antiprotease imbalance can be expected to have the greatest effect on lung disease associated with COPD and AAT deficiency. Ensuing sections will focus on AAT augmentation therapy in both intravenous and aerosolized forms, transgenic and recombinant forms of AAT and administration of either natural (elafin and SLPI) or synthetic (Sivelestat) antiproteases for treatment of COPD.

4.1. AAT replacement therapy

The importance of the protease: antiprotease balance is evident by the development of emphysema in AAT deficient individuals due to unopposed NE activity, of which AAT is the major inhibitor. Indeed the most logical approach to treatment is the reestablishment of physiological levels of AAT. The minimum level of AAT required to protect the lung from protease mediated damage was set as 11µmol/L (or 80mg/dL), and this has been referred to as the “protective” threshold level [129]. This value is based on the levels of AAT recorded in non-smoking individuals with the PiSZ phenotype, which is not thought to confer an increased risk of developing lung disease. Intravenous infusion of human plasma derived AAT, also referred to as AAT augmentation therapy, provides a method of maintaining this protective threshold and thus delays the progression of emphysema (Table 1). In 1981, researchers developed a method for partially purifying AAT from pooled human plasma and with the knowledge that the serum half-life of AAT is 5.4 days [130], devised an infusion schedule that allowed once weekly administration of purified AAT to AAT deficient individuals. Following such infusions the results of this study demonstrated that significant amounts of AAT, with full anti-NE capacity, diffused to the lower respiratory tract. Consequently, infusion of purified human plasma AAT at a dose of 60mg per kilogram of body weight per week, a dose that was sufficient to maintain serum levels ≥ 11µmol/L, was FDA-approved and is now widely used in Europe and North America in treatment of AAT deficient individuals [131]. The first available preparations of AAT included pooled human plasma AAT prepared by pasteurisation (Prolastin, Bayer, West Haven, CT, USA). In turn, more recent studies examined the biochemical effectiveness of AAT purified by solvent detergent and nano-filtration methodology (Aralast, Baxter, Westlake Village, CA, USA) [132] and a third preparation (Zemaira,
CSL Behring, PA USA) has received US FDA approval [133]. Currently there are six FDA approved AAT preparations available in the USA. The clinical effects of infused AAT therapy documented to date consist of patient outcome measures including the rate of FEV\textsubscript{1} decline [134, 135], the level of desmosine as a biomarker of elastin degradation [136, 137], the incidence of acute exacerbations [138], frequency of lung infections [139] and the change in lung density [140] calculated by CT scanning [141]. Nevertheless, though studies have demonstrated that infusion of AAT is safe and well tolerated [142], there remains considerable debate over the clinical benefits and the cost-effectiveness of the treatment [134, 143, 144].

| Study Type               | AAT Infusion | Reference              | Patient outcome                                      |
|-------------------------|--------------|------------------------|-------------------------------------------------------|
| Observational           | Weekly       | (Ma et al. 2013)       | Reduced elastin degradation in treated group           |
| Observational           | Weekly       | (Tonelli et al. 2009)  | Slower rate of decline in FEV1% predicted in augmentation group |
| Randomized              | Weekly       | (Dirksen et al. 2009)  | Attenuated loss of lung tissue in treated cohort measured by CT lung density |
| Observational           | Weekly       | (Wencker et al. 2001)  | Reduced rate of FEV1 decline post augmentation therapy |
| Descriptive             | Weekly       | (Gottlieb et al. 2000) | Elastin degradation was not reduced                    |
| Observational           | 56% weekly & 26% biweekly | (Lieberman 2000)       | Decline in number of infections per year               |
| Randomized controlled   | 4-weekly     | (Dirksen et al. 2009)  | Reduced loss of lung tissue by CT densitometry with augmentation |
| Observational parallel controls | 51% weekly & 25% biweekly | (group 1998) | Slowed decline in FEV1 of 27ml/year in treated group |
| Observational parallel controls | Weekly      | (Seersholm et al. 1997) | Reduced rate of decline of FEV1 in treated group of 21ml/year. |

Table 1. Treatment of patients with AAT deficiency with augmentation therapy

The biochemical efficacy of AAT augmentation therapy has been examined in a number of studies and in 1987 Wewers and colleagues demonstrated that a weekly dosage of 60mg/kg not only restored AAT levels in serum and BAL fluid but also increased anti-NE capacity from a baseline value of 5.4 ± 0.1µM in the serum to 13.3 ± 0.1µM [142]. Indeed, additional studies have focused on the impact of augmentation therapy on the inflammatory environment of the lung. For example, AAT deficiency is characterised by increased neutrophil numbers and thus increased sputum and BAL fluid levels of NE [145]. This burden of neutrophils in the lung as a result of excessive trafficking is attributed to chemotactic agents such as IL-8 and LT\textsubscript{B}\textsubscript{4} and significantly higher levels of these chemo-attractants have been recorded in sputum from individuals with AAT deficiency compared to COPD patients. To understand this further, an
in vitro study discovered increased release of LTB₄ from AAT deficient alveolar macrophages as a result of unopposed NE activity. Of relevance, the addition of exogenous AAT reduced the amount of LTB₄ being released by macrophages in response to NE [146]. In confirmation of this latter study, Stockley et al demonstrated that sputum samples from AAT deficient individuals on day one post infusion of AAT augmentation therapy possessed reduced NE activity and a dramatic attenuation of LTB₄ concentration from a level of 13.46nM to 8.62nM [147]. Moreover, the anti-inflammatory effects of AAT augmentation therapy were confirmed as decreased concentrations of IL-8, and the chemotactic activity mediated by this chemokine, were reduced to normal levels in AAT deficient individuals post treatment. [148, 149]

One of the first studies to examine the effect of AAT augmentation therapy compared the ΔFEV₁ of 97 ex-smokers from a Danish AAT deficient registry to a German group of 198 patients treated with weekly infusions of AAT (60mg/kg) for at least one year. Overall, the ΔFEV₁ in the treated group was significantly lower than in the untreated group, with annual declines of 53 mL yr⁻¹ and 75 mL yr⁻¹, respectively (p=0.02). However, there was no beneficial effect of augmentation therapy in 103 patients with an initial FEV₁ ≤ 30 or in the 25 patients with an FEV₁ > 65% [134]. In 1998, one of the largest observational studies (n=1129) centred on the NHLBI Registry for individuals with severe AAT deficiency [150] was carried out. Although no overall difference in FEV₁ decline was recorded between the augmentation-therapy treated and untreated groups, in a subgroup with FEV₁ between 39-45% predicted there was a significant difference of -27ml/year between treated and untreated. This study also suggested that survival was enhanced in individuals receiving augmentation therapy. The risk ratio for death in augmentation therapy recipients was 0.64, significantly lower than non-recipients (P=0.02) and the risk ratio for individuals receiving augmentation therapy with stage II COPD was 0.21 (P<0.001). The possibility that these differences may have been due to other factors, such as the socioeconomic status of enrolled patients could not be ruled out and this latter point is a potential limitation of this study. In a subsequent randomised study of 164 AAT deficient individuals enrolled in the Alpha-1 foundation DNA and tissue bank, when adjusted by age at baseline, sex, smoking status, baseline FEV₁ % of predicted, a slower rate of decline in FEV₁% predicted was observed in the augmentation group (10.6±21.4 ml/year) in comparison to the non-augmented group (36.9±±12.1ml/year). The authors of this study concluded that augmentation therapy was effective in subjects with AAT deficiency, favouring ex-smoker subjects with an FEV₁ below 50% of predicted [151].

Results from studies measuring changes in urine desmosine levels, a marker of elastin breakdown, in response to AAT augmentation therapy have been mixed. One study of two AAT deficient patients observed a 35% reduction in urine desmosine levels after monthly doses of 260mg/kg AAT [152]. In contrast, a larger study by Gottelieb et al showed no change in the level of elastin breakdown after eight weeks of augmentation therapy (P=0.85). Although this latter study recruited only twelve AAT deficient individuals, the authors suggested that elastin degradation at this point in the disease was possibly NE independent [137]. In a recent study desmosine levels were assessed in plasma, BAL fluid and urine in a cohort of AAT deficient patients receiving AAT augmentation therapy. A 13.9% reduction in plasma and 37% reduction in BAL fluid desmosine levels were observed 12 weeks after receiving IV augmentation
therapy compared to baseline levels prior to treatment [153]. The study showed that augmentation therapy maintained the ability to inhibit NE and to reduce degradation of elastin both systemically and in the lungs, however the findings suggested that the dose of AAT was not sufficient to reduce elastin degradation to that of control levels of healthy individuals. There is a relatively limited body of clinical evidence supporting the benefits of 60mg/kg dosage, with some even questioning the recommendation of this dose of AAT to AAT deficient patients [154]. The concentration of 60mg/kg aims to increase AAT levels to values above that of the protective threshold (11µM) yet levels are still below that of serum AAT concentration observed in non-AAT deficient individuals (20-53µM) [155]. To address this issue Campos et al assessed the safety and efficacy of an increased 120mg/kg weekly dose of AAT in 30 adults with AAT deficiency in a multicentre, randomised, double-blind crossover study. A weekly dose of 120mg/kg resulted in a serum concentration of 27.7µM four weeks after treatment, well within the healthy control range, compared to 17.3µM at the same time period for the group receiving 60mg/kg. Concurrently, this increased dosage was considered to be safe and well-tolerated, however further investigation is warranted due to the relatively small cohort size and the lack of analysis of clinical parameters such as FEV₁ and CT densitometry [156].

Currently desmosine is the only clinical biomarker for assessment of lung tissue destruction, however it is limited by lack of specificity and may be influenced by diet and renal function which may in part provide an explanation for the lack of association between desmosine levels in the urine and FEV₁ [157-159]. Current research is aimed at identifying cost effective yet stable novel biomarkers that are central to the pathophysiological process, which can act as a predictor of disease progression and are sensitive to therapeutic intervention [160, 161]. In this regard, a novel potential biomarker has been recently reported specific to cleavage of fibrinogen and related to NE in the lungs [136]. The fibrinogen cleavage product Aα-Val³⁶⁰ was measured in plasma from subjects recruited in the EXACTLE trial and the levels of this product were decreased in subjects receiving AAT replacement therapy while remaining unchanged in the placebo group.

Determining exacerbation rates in patients receiving therapy is an additional parameter that is employed to determine the efficacy of AAT replacement therapy. In a web based questionnaire prepared by Lieberman and colleagues, key questions addressed issues such as frequency of respiratory infections pre- and post-AAT augmentation therapy [139]. Out of eighty nine individuals who had received augmentation therapy for more than one year, seventy four felt that the treatment was of benefit, with almost half accrediting the benefits to a reduction in the number of infectious exacerbations from approximately five down to one per year (P<0.001). CT lung density measurements are currently considered to be a more sensitive outcome to measure the impact of AAT replacement therapy. The first of these studies was a double blind trial with 26 Danish and 30 Dutch ex-smokers, randomized to either AAT (250 mg/kg) or albumin (625 mg/kg) infusions at 4 week intervals for at least 3 years [140]. Using self-administered spirometry, no difference was found in FEV₁ decline between treatment and placebo. Conversely, upon analysis of CT scans (slices 5 cm below carina), a trend towards a slower rate in loss of lung density was observed in augmentation receiving patients with measurements of 2.6 ± 0.41 g/L/yr for placebo as compared with 1.5 ± 0.41 g/L/yr for AAT.
infusion, however the reported differences were shown to be non-significant (P=0.07), possibly due to the inadequate study size. Following this, in 2009, Dirksen et al. carried out a randomised, double-blind, placebo-controlled, parallel-group study conducted at three European centres (Copenhagen (Denmark), Birmingham (UK), and Malmö (Sweden)) known as the EXACTLE trial. CT scans were performed at baseline and at 12 and 24 months and the difference in the decline of lung density between treated and placebo groups suggested a trend towards a beneficial treatment effect, with P values for treatment difference ranging from 0.049 to a non-significant value of 0.084 depending on the outcome algorithm chosen. In 2010, Stockley and colleagues analysed the combined outcome measures of the EXACTLE and Danish-Dutch trial and concluded that augmentation therapy conferred a significant decline in the rate of CT densitometric loss but not in FEV$_1$ decline [162].

A number of studies have addressed the potential clinical use of AAT augmentation therapy in treatment of disorders outside the context of AAT deficiency, including transplant rejection, type1 diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, viral infection and cystic fibrosis [163]. In light of this, there is a need that goes beyond that afforded by purified human plasma and thus transgenic and recombinant AAT have been considered.

4.2. Recombinant and transgenic AAT

Despite the accumulation of encouraging data supporting the use of AAT augmentation therapy, significant questions remain regarding the cost-effectiveness of this intravenous strategy for treatment of AAT deficient related COPD, which is estimated to cost the US $100,000 per patient per year worldwide [143]. Such deliberation has prompted the development of new strategies, including the use of recombinant and transgenic protein to boost the natural antiprotease screen. A variety of systems have been employed to produce humanized recombinant AAT including plants, yeast fungi, animals, insect cells, bacteria and mammalian cells. One of the approaches involved expression of recombinant AAT in *E. coli*, but AAT produced via this system lacked glycosylation and consequently exhibited a short half-life within the circulation. To address this issue the presence of a single thiol residue at the surface of AAT was exploited by researchers, who conjugated maleimido-polyethylene glycol to the thiol group. Results revealed that site-specific conjugation with polyethylene glycol at Cys$^{232}$ of nonglycosylated recombinant human AAT gave rise to active inhibitor with prolonged in vivo stability [164]. An alternative approach included production of a secreted fully functional AAT by the yeast *Saccharomyces cerevisiae* [165]. This secreted protein had high mannose-type glycosylation [166], which was thought to give rise to an immune response in humans because of non-human glycan residues, an adverse effect shared by active recombinant AAT protein expressed in the insect cell baculovirus expression vector system [167]. In an attempt to overcome the issue of glycosylation, a method of hyper glycosylation of the protein was introduced. This was achieved by adding terminal sialic acids to the existing glycans on the human AAT molecule. Such modification conferred increased protein half-life while maintaining the anti-NE capacity of the protein when injected into a mouse model [168]. In a further attempt to prepare fully glycosylated human AAT, Blanchard et al employed a human neuronal cell line (AGE1.HN®) to produce a recombinant AAT protein which retained biological activity and
displayed a similar glycosylation patterns to native AAT [169]. Moreover, the recombinant AAT protein was biologically active and maintained anti-elastase activity and anti-inflammatory capacity, including modulation of TNFα production in neutrophils and monocytes [169]. *In vitro* testing of this protein revealed that the inhibitory effect of the recombinant AAT was comparable to that of Prolastin, however this has yet to be confirmed *in vivo*. More recently, AAT has been successfully produced and purified from the human PER.C6 cell line. The resultant protein shares the same primary, secondary and tertiary structures and *N*-linked glycosylation sites as AAT derived from human plasma and exhibits equivalent anti-NE capacity [170, 171]. While these studies strengthen the argument for the therapeutic use of recombinantly produced AAT, issues still remain with regards to the safety and efficacy of protein produced in this manner.

Subsequently, it was envisaged that sources of recombinant AAT from transgenic animals might overcome this posttranslational glycosylation challenge and fulfil the demand for mass production of AAT. To this end rabbits [172], mice [173] and sheep transgenic for a fusion of the ovine beta-lactoglobulin gene promoter to the human AAT genomic sequences were generated [174]. Human AAT purified from the milk of these animals appeared to be fully *N*-glycosylated and biologically active. While the use of transgenic sheep certainly tackled the issue of cost effectiveness, 5,000kg of AAT could be produced in one year, unfortunately however, a trial of inhaled AAT derived from sheep milk proved disappointing and observations of a systemic antibody response in recipients to residual native sheep AAT and alpha-1 antichymotrypsin were observed [175]. Thus it is clear that transgenic preparations of AAT will only be of therapeutic value if they are of high purity in order to avoid immunogenicity.

While enhancing production of AAT seems promising from a cost and mass production point of view, significant challenges remain for the development of recombinant and transgenic AAT and they cannot compete with the current source of AAT from pooled human plasma for safety and efficacy in the treatment of AAT deficiency.

### 4.3. Aerosolized AAT augmentation therapy

Interest in the administration of AAT in aerosolized form has increased in recent years due to the advantageous properties provided such as a direct route to the lungs, avoidance of systemic deliver and a reduction in costs. Aerosolization of AAT has been shown to increase AAT levels and to restore anti-NE capacity in lung epithelium lining fluid of both COPD and cystic fibrosis individuals [176]. AAT administered in aerosolized form was found to positively impact upon neutrophil mediated killing of *Pseudomonas* [177], possibly by preventing cleavage of neutrophil complement receptors by serine proteases, a previously reported adverse effect of NE [178] or by preventing cleavage of CXC chemokine receptor 1 (CXCR1) [179]. In addition, the presence of increased AAT in serum post aerosolization supports the hypothesis that augmented AAT is capable of diffusing across the pulmonary interstitium after administration [180] and affords anti-NE protection to the interstitial compartment [176]. Measurements of the rate of transfer of AAT from the lung and of the rate of appearance of AAT in plasma resulted in a calculated permeability of the alveolar-capillary membrane to AAT of 3.49-6.39 X 10⁻¹⁰ cm/s. In a canine model, levels of AAT rose to a maximum value at 48 hours after
administration, remained elevated from 48-72 hours, and then declined slowly by 144 hours after administration [180]. Comparable results were reported by Hubbard et al. who evaluated aerosol administration of recombinant AAT to COPD individuals with AAT deficiency. Post aerosolization of single doses of 10-200mg of AAT, AAT anti-NE defences in ELF were augmented and aerosolized AAT was detectable in serum indicating that recombinant AAT was capable of gaining access to lung interstitium [176].

Further support for the use of aerosolized AAT in treatment of COPD was provided by Griese and colleagues who examined the effect of four weeks of plasma purified AAT inhalation on lung function, protease–antiprotease balance and airway inflammation in patients with cystic fibrosis [181]. The authors reported an increased concentration of aerosolized AAT accumulation in the airways. Post treatment, levels of NE activity, numbers of infiltrating neutrophils, pro-inflammatory cytokines levels and the numbers of bacteria (*P. aeruginosa*) were reduced culminating in a marked reduction in airway inflammation. In a second study by this research group, the authors documented that the inability of neutrophils to eradicate *Pseudomonas* infection despite the abundance of neutrophils in the cystic fibrosis lung was due to cleavage of CXCR1 from the neutrophil. *In vivo* administration of aerosolized AAT was shown to restore CXCR1 expression and improve the killing capacity of neutrophils as assessed by sputum levels of *P. aeruginosa*, thus supporting the beneficial effects of aerosolized AAT therapy [179].

In a further study employing a mouse model of smoke induced emphysema, inhaled AAT resulted in reductions in airspace enlargement of up to 73%. The results of this investigation indicated that delivery of AAT directly to the lung can prevent NE mediated tissue damage. Moreover, further evidence of the ability of aerosolised AAT to directly protect the lung tissue from proteolytic breakdown was demonstrated as aerosolised AAT abrogated NE-induced expression of cathepsin B and MMP-2 in BAL fluid, thus indirectly protecting key anti-inflammatory and antimicrobial peptides including SLPI and lactoferrin from cathepsin mediated proteolysis within the milieu of the COPD lung [36]. In terms of clinical efficacy of aerosolised AAT, a phase III trial of inhaled Kamada AAT is currently on-going with results on outcome measures including safety and efficacy, exacerbation frequency and progression of emphysema to be released presently. The outcome of this study will be pivotal to shaping the future development of aerosolised AAT augmentation therapy (NCT01217671).

### 4.4. Naturally occurring antiproteases elafin and SLPI as therapies for COPD

A number of studies have generated data to support the use of naturally occurring antiproteases, other than AAT, as potential anti-inflammatory therapies to modulate the high level of inflammatory within the lungs of COPD patients. Within the literature reports suggest that serine protease inhibitors may potentially be used as a treatment option for COPD. One such antiprotease is elafin, a small cationic protein (6kDa) which is a member of the chelonianin family. Throughout the literature it is often referred to as skin derived anti-leukoprotease (SKALP) due to its first identification in psoriatic epidermis [182]. More recently however, it has been shown to be produced and released by epidermal keratinocytes [183], lung derived epithelia [184], T-cells [185], macrophages [186] and also neutrophils [187].
Elafin is a subunit derived from the precursor molecule trappin-2 which has a molecular weight of 12.3 kDa [188]. The conversion of trappin-2 into elafin can occur by cleavage by several proteases including cathepsin L, cathepsin K, plasmin, trypsin but the most efficient protease at releasing elafin is tryptase [189]. The mature form of trappin-2 consists of two domains; the first domain is unique to only trappin-2, the N-terminal cementoin domain. This domain aids as a transglutaminase substrate which allows trappin-2 to interact and bind to extracellular matrix proteins such as fibronectin, collagen IV, fibrinogen, laminin V, vitronectin, thus prolonging its presence within in the lung [188]. The second domain, which is present in both trappin-2 and elafin, is the whey acidic protein (WAP) domain. The WAP domain provides antiprotease activity with specificity against NE [18] and PR3 [17], two key proteases that play a role in the lung pathophysiology associated with COPD [56, 190].

Several studies have demonstrated that elafin is produced under inflammatory conditions suggesting it to be an acute phase reactant [191]. Interestingly, NE can impact on elafin expression and it has been demonstrated that exposing human alveolar epithelial cells to NE can result in increased protein expression and secretion of elafin [192]. Additional studies have demonstrated that pro-inflammatory mediators such as TNFα and IL-1β increase elafin expression in lung derived cell lines, indicating that in response to cytokine induced inflammation, epithelial cells can increase their antiprotease shield [191]. This induced increase in elafin expression is not limited to only host derived inflammatory mediators as it has been shown that bacterial LPS can increase elafin expression in murine airways [193] and in macrophages from transgenic mice expressing human elafin [194].

The immuno-modulatory impact of elafin on inflammation has been established in a number of studies and animal models. For example, Vachon and colleagues utilised a murine model and following intranasal administration of LPS, pre-treatment with recombinant human elafin was shown to diminish neutrophil infiltration into the airways [195]. In the same study elafin was shown to reduce gelatinase activity, macrophage inflammatory protein-2 (MIP-2), keratinocyte chemoattractant and significantly reduced mRNA levels of three members of the IL-1 ligand family [195]. Conversely, in an earlier study involving a transgenic murine model expressing human trappin-2, an increase in neutrophil recruitment to the lungs of LPS challenged mice was observed [193]. The discrepancy between these two latter studies could in part be due to differences in the mode of elafin administration and the murine models employed. Of interest, the positive impact of elafin on COPD related complications such as pulmonary hypertension has been reported [196]. Moreover, in a hypoxia associated pulmonary hypertension murine model the protease activity, muscularization of pulmonary arteries and right ventricular pressure were reduced in transgenic mice that over expressed elafin [197]. Indeed, both elafin and its precursor molecule trappin-2 have anti-inflammatory properties, as evident by the inactivation of key inflammatory signalling pathways and immune cell activity associated with COPD pathogenesis. In a study using a human myelomonocytic cell line, elafin was shown to exert its anti-inflammatory effect intracellularly [198]. The mode of action involved direct impact on the ubiquitin-proteasome pathway, delaying turnover of polyubiquitinated proteins thus affecting NFKB activation and the AP-1 pathway leading to reduced MCP-1 expression in response to LPS [198]. Moreover, in transfection
studies it was demonstrated that the impact of elafin on chemokine production was cell specific [199]. Results demonstrated that elafin reduced TNFα secretion by human macrophages and IL-8 release by human umbilical cord endothelial cells (HUVECs) in response to TNFα, LPS and oxidized LDL, through modulation of NFκB signalling. In contrast, in the same study transfecting an alveolar epithelial cell line with elafin had no significant effect on LPS induced IL-8 production [199].

In addition to possessing antiprotease and anti-inflammatory properties, elafin also demonstrates anti-microbial properties which may prove beneficial in the treatment of infective exacerbations in COPD patients. In a study carried out by Simpson et al., the anti-bacterial capability of elafin was evaluated and the results demonstrated that elafin maintained bactericidal effect against both *P. aeruginosa* and *S. aureus* [200]. This effect could in part be due to the cationic charge of elafin which may destabilize bacterial membranes similar to classical antimicrobial proteins [201]. Moreover, a study by Baranger et al., demonstrated that trappin-2 had antibacterial properties against other clinically important bacteria including *Klebsiella pneumoniae*, *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Branhamella catarrhalis* [202]. Furthermore, this study highlighted the novel anti-fungal effect of trappin-2 against *Aspergillus fumigatus*, with the outcome of this study demonstrating the anti-microbial properties of trappin-2 to be independent of its antiprotease property. Aside from direct activity against microbes, trappin-2 in turn has been shown to enhance the clearance of *P. aeruginosa* from the lungs of infected mice [203], an effect mediated via opsonisation of bacteria with trappin-2 for more efficient CD14-dependent clearance by macrophages [197]. In additional studies it has been shown that elafin can modulate inflammation associated with LPS, through inhibition of AP-1 and NFκB activation [198], possibly by direct interaction with this microbial inflammatory mediator [204].

These innate attributes of elafin make it an ideal candidate for a replacement therapy in treatment of inflammatory lung diseases such as COPD which is associated with excess protease burden and/or infection. However caution must be exercised, as like many other endogenous protease inhibitors, elafin is susceptible to inactivation by neutrophil-derived oxidants resulting in loss of its antiprotease activity [205]. Moreover, elafin can be cleaved by NE [206], which is present in high concentrations in the COPD lung [207] and cleavage can result in diminished ability of elafin to bind LPS and its capacity to be immobilized by transglutamination [206]. A similar observation was made in regard to the *P. aeruginosa* derived proteases pseudolysin and aeruginolysin which can cleave elafin thereby negatively impacting on its biological functions [208]. Collectively, these findings suggest that within an environment of high protease burden, as found in the COPD lung, this could have a negative impact upon the clinical efficacy of elafin.

An additional native antiprotease that has been well documented for its potential as a therapy for COPD is human SLPI, which was originally identified in parotid secretions [20]. Being a member of the antileukoprotease family, SLPI shares 40% homology with elafin. A number of cell types have been documented to produce SLPI including macrophages [186], monocytes, neutrophils [187] and lung epithelial cells [209]. It is well accepted that SLPI is a potent inhibitor of an array of serine proteases including NE, cathepsin G, trypsin and chymotrypsin. Similar
to elafin, SLPI expression levels are increased post inflammatory mediator exposure; for example TNFα and IL-1β treatment of lung epithelial cells [191]. Other host derived inflammatory proteins including proteases from neutrophils (e.g. NE and defensins [184]) can increase and induce SLPI expression in bronchial epithelial cells. In more recent studies, aside from host derived inflammatory mediators, bacteria have also been shown to induced SLPI expression in macrophages by a TLR2-dependent but MyD88-independent signalling pathway [210]. Additionally, bacterial products such as LPS can increase SLPI expression in macrophages and neutrophils [211], suggesting that SLPI functions as an acute phase reactant.

SLPI exhibits an array of anti-inflammatory properties including inhibition of monocyte production of MMPs [212, 213] which play an important pathophysiological role in tissue remodelling and are observed to be in high abundance in COPD [95, 107, 214]. The range of anti-inflammatory properties of SLPI includes inhibition of nitric oxide and TNFα production in macrophages in response to LPS [215] and inhibition of IFN-γ induced cathepsin S expression in macrophages [216]. In monocytes it has been demonstrated that SLPI can cross the plasma membrane and enter the cell cytoplasm and nucleus [217]. Localization to these cell compartments facilitates the ability of SLPI to inhibit degradation of key proteins that activate NFκB and to competitively compete with p65 binding to NFκB consensus sequences thereby preventing NFκB binding to promoter regions of inflammatory genes [217]. In a more recent study involving neutrophils from COPD patients, the intracellular inhibitory activity of SLPI was further expanded as it was shown that SLPI modulated calcium flux and inositol 1,4,5-triphosphate generation thereby reducing cell migration [218]. Additionally, SLPI possesses anti-microbial capabilities against *P. aeruginosa, S. aureus, S. epidermidis, E. coli* and *S. aureus* [219, 220]. SLPI’s antifungal properties have been observed against *A. fumigatus* and *Candida albicans* [221] and in this latter study SLPIs fungicidal and fungistatic activity were shown comparable to that of human defensins and lysozyme.

Despite the potential advantages, delivery of SLPI to the lungs has proven unimpressive [222]. Aerosolisation of recombinant SLPI (100mg) twice daily to individuals with cystic fibrosis was associated with reduced NE activity on the respiratory epithelial surface, as well a reduction in the level of IL-8 and neutrophil numbers [223]. However, a greater concentration of recombinant SLPI compared to AAT is required to suppress NE activity in individuals with lung disease. Furthermore accumulation of recombinant SLPI on respiratory epithelial surfaces does not occur and SLPI does not penetrate significantly into the interstitium following aerosolization. Further drawbacks include the fact that most of the anti-NE effects are gone within 12 hours of administration. Reasons for this latter phenomenon have been proposed and may be due to uptake of SLPI by epithelial cells and macrophages, and/or binding of recombinant SLPI to molecules in the interstitium after passing through the epithelium [222, 224].

More recently, it has also been shown that SLPI is vulnerable to degradation and inactivation by cysteinyl cathepsins [225] and NE [21], and thus the utilization of SLPI as effective therapy for COPD presents some challenges. One approach to this challenge is delivery of recombinant SLPI via a liposomal carrier which protects the activity of SLPI against cathepsin L mediated degradation, whilst having no adverse effect on SLPI access to intracellular sites of action in
vitro [226]. Alternatively, co-treatment of SLPI with surfactant protein A has been proposed, which aids in the preservation of SLPI and protects it from cleavage by matrix metalloproteases [227].

4.5. Synthetic and semi-synthetic engineered protease inhibitors as alternative therapies for COPD

In a COPD animal model, ADAM-17 (a membrane bound MMP) has been shown to contribute to progression of COPD lung disease through activation of TNFα [228]. Recent studies have demonstrated that AAT, a natural serine protease inhibitor, also acts as an ADAM-17 inhibitor thereby regulating soluble immune complex induced neutrophil chemotaxis [148] and TNFα production in lung endothelial cells [229]. However, other therapeutic options for the modulation of inflammation associated with excessive protease activity is the use of synthetic or semi synthetic protease inhibitors. These molecules, for example the non-peptide inhibitor ONO-5046 or sivelestat, offer better accessibility into the lung milieu due to their reduced size. Sivelestat is a specific inhibitor of NE and in LPS animal studies was shown to significantly reduce the number of infiltrating neutrophils and elastase activity levels, thereby decreasing lung tissue damage [230-232]. Moreover, sivelestat has been reported to reduce neutrophil-mediated endothelial cell injury by inactivating extracellular elastase and by suppressing release of this serine protease by neutrophils [231]. A recent study demonstrated the ability of sivelestat to inhibit bleomycin induced pulmonary fibrosis and apoptosis in human epithelial cells [233]. The authors of this study also verified that sivelestat reduced pulmonary neutrophil counts by decreasing BAL fluid levels of cytokine-induced neutrophil chemoattractant (CINC)-1. So far there have been no in vitro or in vivo investigations on the potential use of sivelestat in COPD, but studies involving other pulmonary conditions including post-cardiopulmonary bypass lung injury [234], acute lung injury with sepsis [235] and adult respiratory distress syndrome [236] have shown some therapeutic success with this synthetic inhibitor. To date, Japan has been the only country to approve sivelestat for the above conditions [237].

An alternative synthetic inhibitor that has been utilized in several studies is the cyclic thiol compound MR889. This synthetic inhibitor demonstrated inhibition against several serine proteases in vitro and in sputum from patients with chronic bronchitis [238]. When used in clinical studies however, although MR889 was considered safe for COPD patients, the results demonstrated that there was no significant reduction in the level of biomarkers of lung disease except for a small subset of individuals who had a short disease duration [239]. Other synthetic elastase inhibitors such as ZD0892 and FR134043 have been shown to reduce lung inflammation associated with cigarette smoke [240, 241] or NE [242] in animal models and in cultured cells [243]. ZD0892 was shown not to exert an adverse effect on neutrophil function including uptake and killing of S. aureus, but use of this compound in clinical studies in humans has not been documented.

More recently, the synthetic selective inhibitor of elastase, AZD9668, has attracted a lot of attention and was shown to have significant impact on NE activity in vitro [244]. In rodent models, AZD9668 was shown to prevent NE-induced lung injury, cigarette smoke induced
inflammatory responses, airspace enlargement and small airways remodelling [244]. Despite these positive findings however, results of a recent clinical trial involving AZD9668, queried the efficiency of this inhibitor in COPD patients as no significant change in lung function and clinical measurements was observed [245]. Although these later results suggest that targeting NE activity alone may not be an effective treatment option in COPD, a subsequent smaller study indicated the potential clinical efficacy of AZD9668 in the treatment of bronchiectasis [246].

Aside from serine proteases, and as already mentioned, MMPs also play a key role in the development of COPD. TIMPs are endogenous MMP inhibitors and in COPD, MMP activity levels associated with lung disease are not counteracted by TIMPs [247]. To date no native TIMPs have been used as potential therapeutics, but synthetic and selective MMP inhibitors have been well documented. The orally administered MMP-9 and MMP-12 inhibitor AZD1236 was well tolerated by patients in two separate clinical trials but overall it was deemed to have no effect on clinical parameters [248] or disease related biomarkers in COPD patients [249]. In a recent study by Wu et al., several potential MMP-12 inhibitors were analysed in vivo, with one specific inhibitor, Compound 26, modulating cell infiltration into the lungs of mice with MMP-12 induced inflammation [250]. Similar findings were observed for a second MMP-12 inhibitor, Compound 14 [251]. An additional in vivo study involved the use of the broad spectrum MMP inhibitor RS113456, which possessed comparable anti-inflammatory properties to AAT [252]. In the latter study the authors noted multi-facetted attributes of RS113456, whereby this MMP inhibitor reduced neutrophil influx, modulated NFκB activity and reduced MCP-1 and MIP-2 expression in the short term [252].

Other synthetic MMP inhibitors evaluated in cigarette smoke induced models of COPD have shown significant reductions in lung macrophage numbers [126], neutrophilia [253, 254], elastase/ MMP levels [254], air space enlargement [126, 254] and inflammatory markers [90, 126]. To date the benefits of MMP inhibitors has only been assessed in animal models and their successful use as therapeutics for treatment of COPD in humans has not been reported. Thus caution needs to be exercised due to the potential for tumour growth promotion as a result of inhibition of angiogenesis factors [255].

An alternative to synthetic inhibitors is the production of semi-synthetic protease inhibitors. These agents are created through the chemical modification of naturally occurring protease inhibitors. One such semi-synthetic inhibitor is the engineered protein inhibitor of human NE (EPI-HNE-4) which is derived from the Kunitz type domain from the naturally occurring inter α inhibitor. EPI-HNE-4 has been shown resistant to degradation by both human and bacterial MMPs and its antiprotease activity was reported impervious to oxidative inhibition [256]. Further studies involving the use of a rat model and sputum from cystic fibrosis patients demonstrated the anti-NE capacity of EPI-HNE-4 along with its ability to decrease neutrophil migration towards the bacterial peptide N-formyl-L-methionyl-L-leucyl-phenylalanine [257]. Subsequently however, contrary data on the immuno-regulatory effects of this inhibitor have been documented as Honoré et al., demonstrated that EPI-HNE-4 had little effect on neutrophil migration or impact on bacterial clearance in a P. aeruginosa model of pneumonia [258].
Within this expanding field of potential antiprotease therapies lies the development of novel chimeras that are active against NE, PR3 and CathG. A study by Zani et al., reported on the development of a chimera consisting of domains from both elafin and SLPI and a trappin-2 variant (A62L) [259]. The authors demonstrated that both A62L and the elafin-SLPI chimera retained their polypotent inhibition of protease activity while covalently cross-linked to fibronectin or elastin by a tissue transglutaminase, in a similar fashion to wild-type elafin and trappin-2 [188]. A recent extensive study on A62L in an epithelial cell line demonstrated that this engineered trappin-2 molecule prevented neutrophil and protease induced epithelial cell injury by inhibiting cell detachment, tight junction disruption and ultimately reducing apoptosis [260]. Although the preliminary data has been generated for these engineered antiproteases, overall their effect on the inflammatory status and clinical parameters in COPD patients remains to be investigated.

5. Conclusion

Extensive studies have been performed to extend our knowledge of the involvement of proteases in respiratory manifestations of COPD, the outcome of which has served to illustrate the multifactorial complexity of the disease (Figure 2). Nevertheless, this clinical and scientific knowledge has advanced the design of both fundamental and novel therapeutic strategies, directed at relieving the protease burden associated with this disorder (Table 2). There have been major advances in the evaluation of AAT augmentation therapy in the treatment of the lung disease associated with AAT deficiency with newer focus on aerosolization approaches. These studies will inevitably show within the next number of years whether this approach works clinically. No single treatment that effectively prevents activity of the broad spectrum of proteases present in the airways is available as yet. Such pharmacological approaches including the development of antiprotease chimeras would essentially correct lung disease processes and conceivably exert anti-inflammatory effects. However, this would require a more complete understanding of the mechanism of disease and of the action of presently accessible and newly discovered drugs.

| Protease           | Role in COPD pathogenesis | Inhibitors and inactivators                                  | Clinical trials and evidence for antiproteases as therapeutics                      |
|--------------------|---------------------------|------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Neutrophil Elastase| Elastolysis/destruction of extracellular matrix proteins including elastin, collagens, fibronectin, proteoglycans & laminin Cleaves epithelial cell surface receptors Cleaves signalling cytokines | Alpha-1 antitrypsin (AAT) Monocyte neutrophil elastase inhibitor (MNEI/ Serpin B1) Elafin Secretory leucocyte protease inhibitor (SLPI) | Intravenous augmentation therapy of AAT. (Multiple Clinical Trials in Humans, see Table 1) Clinical effects of IV AAT in AATD: Slows rate of FEV1 decline Reduces elastin degradation Reduces exacerbation frequency |
| Protease          | Role in COPD pathogenesis                                                                                                                                                                                                 | Inhibitors and inactivators                                                                                       | Clinical trials and evidence for antiproteases as therapeutics                                                                 |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Protease-3 (PR3) | Elastolysis/destruction of extracellular matrix proteins including elastin, collagens, fibronectin, proteoglycans & laminin. Less destructive than NE, Pro-inflammatory, activates TNFα and IL-1β, Hypersecretion of mucus, Cellular apoptosis | Alpha-1 antitrypsin (AAT)                                                                                           | See above for clinical effects of AAT therapy in AATD and COPD                                                          |
|                  |                                                                                                                                                                                                                       | Sivelestat (synthetic non-peptide inhibitor) MR889 (synthetic cyclic thiol compound) ZD0892 (synthetic elastase inhibitor) FR134043 (synthetic elastase inhibitor) AZD9668 (synthetic selective elastase inhibitor) | Attenuates loss of lung density Clinical effects of aerosolized AAT: Restores anti-NE capacity (176, 177) Improved neutrophil killing of P. aeruginosa (179) Outcome of phase III clinical trial pending (NCT 0217671) SLPI – Reduced NE activity and reduced IL-8 levels in CF patients (223) Sivelestat – Reduced number of neutrophils in BAL Has shown therapeutic benefit in acute lung injury and ARDS, but no trials in COPD to date (230-232, 235, 236) MR889 – Safe but no significant reduction in the level of biomarkers of lung disease in COPD patients (239) ZD0892 & FR134043 – Reduce cigarette induced lung inflammation, but no human trials to date (240,2410) AZD9668 – Decreased NE activity in vitro (244) No change in clinical parameters in COPD (245) |
### Protease Role in COPD pathogenesis | Inhibitors and inactivators | Clinical trials and evidence for antiproteases as therapeutics
---|---|---
**Cathepsin G** | Proteolysis and destruction of extracellular matrix of the lung<br>Induces mucus secretion<br>Impairs T-cell function | Alpha-1 antitrypsin (AAT)<br>Secretory leucocyte protease inhibitor (SLPI) | See above for clinical effects of AAT therapy in AATD and COPD

**Other Cathepsins**<br>(Cathepsin B, D, H, K, L and S) | Parenchymal destruction and emphysema development<br>Proteolytic degradation of beta-defensins thus impairing bacterial killing<br>Induce airway inflammation | Cystatins are a group of endogenous reversible, tight-binding competitive cysteine protease inhibitors for cathepsins B, H, and L<br>SLPI inhibits cathepsin S expression in macrophages | 

**Matrix Metalloprotease-12**<br>(MMP-12) | Degradation of collagen and elastin<br>Monocyte recruitment<br>Activates TNFα<br>Induces IL-8 production<br>Can degrade AAT | Tissue inhibitors of metalloproteases (TIMP)<br>Secretory leucocyte protease inhibitor (SLPI)<br>AZD1236 (synthetic inhibitor of MMP-12 and MMP-9)<br>Compound 26 (synthetic compound)<br>Compound 14 (synthetic compound)<br>RS113456 (synthetic MMP-12 inhibitor) | SLPI – Anti-inflammatory properties and specifically inhibits monocyte production of MMPs (212, 213)<br>AZD1236 – Well tolerated in COPD but not effect on clinical parameters (248,249)<br>Compound 26, Compound 14, RS113456 – Reduced neutrophilic inflammation but no human trial data (250-252)

**Matrix Metalloprotease-1**<br>(MMP-1) | Degradation of collagens, elastin, gelatin, pro-MMP9, pro-MMP13<br>TACE (TNFα converting enzyme) like activity<br>Induces TGFβ-1 – leading to fibrotic changes<br>Induces mucus hypersecretion | Tissue inhibitors of metalloproteases (TIMP)<br>Secretory leucocyte protease inhibitor (SLPI)<br>AZD1236 (synthetic inhibitor of MMP-12 and MMP-9) | SLPI – Anti-inflammatory properties and specifically inhibits monocyte production of MMPs (212, 213)<br>AZD1236 – Well tolerated in COPD but no effect on clinical parameters (248,249)

**Other Matrix Metalloproteases**<br>(MMP-2, MMP-8, MMP 10, MMP-13) | Degradation of collagens, gelatin, pro-MMP9, pro-MMP13<br>TACE (TNFα converting enzyme) like activity | Tissue inhibitors of metalloproteases (TIMP) | 

---

See above for clinical effects of AAT therapy in AATD and COPD.
Protease | Role in COPD pathogenesis | Inhibitors and inactivators | Clinical trials and evidence for antiproteases as therapeutics
--- | --- | --- | ---
 | Degradation of collagens, elastin, gelatin and fibronectin | Tissue inhibitors of metalloproteases (TIMP) |  

Table 2. Summary table listing the various proteases, their targets, their inhibitor/inactivators, and clinical trials.

Figure 2. The effect of protease activity on the pathophysiology of COPD. A diagramatic illustration of the primary effects of excessive protease activity on inflammation in COPD. The effects include activation of signalling pathways and proteases, to cleavage and degradation of matrix proteins and antiproteases. The secondary effect of the excessive protease burden in the COPD lung can result in tissue destruction/remodelling and excessive cytokine and mucin production. Consequently proteases play a key role in emphysema, neutrophil influx, inflammation, mucus production and infection. As shown by the red lines, antiprotease therapy (AAT, SLPI and elafin) can impact on several aspects of this complex and intertwined pathway and potentially modulate disease progression.
Acknowledgements

This work was supported by the Medical Research Charities Group/Health Research Board, Science Foundation Ireland (grant number 11/RFP/BMT/3094), the US Alpha One Foundation and the Program for Research in Third Level Institutes (PRTLI) administered by the Higher Education Authority and Science Foundation Ireland.

Author details

Cormac McCarthy, Ciara A. O’Dwyer, David A. Bergin, Noel G. McElvaney and Emer P. Reeves*

*Address all correspondence to: emerreeves@rcsi.ie

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland

References

[1] Hedstrom L. Serine protease mechanism and specificity. Chemical reviews. 2002;102(12):4501-24. Epub 2002/12/12.

[2] Rooney CP, Taggart C, Coakley R, McElvaney NG, O’Neill SJ. Anti-proteinase 3 antibody activation of neutrophils can be inhibited by alpha1-antitrypsin. American journal of respiratory cell and molecular biology. 2001;24(6):747-54. Epub 2001/06/21.

[3] Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365(9478):2225-36. Epub 2005/06/28.

[4] Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2009;34(2):475-88. Epub 2009/08/04.

[5] Hiemstra PS, van Wetering S, Stolk J. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1998;12(5):1200-8. Epub 1998/12/24.

[6] Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert opinion on therapeutic targets. 2008;12(2):145-57. Epub 2008/01/23.
[7] Stockley RA. The role of proteinases in the pathogenesis of chronic bronchitis. American journal of respiratory and critical care medicine. 1994;150(6 Pt 2):S109-13. Epub 1994/12/01.

[8] Donnelly SC, MacGregor I, Zamani A, Gordon MW, Robertson CE, Steedman DJ, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. American journal of respiratory and critical care medicine. 1995;151(5):1428-33. Epub 1995/05/01.

[9] Bieth JG. Elastases: catalytic and biological properties. In: RP M, editor. Regulation of Matrix Accumulation. Orlando, FL: Academic Press; 1986. p. 218–320.

[10] McElvaney NG CR. Proteases and lung injury. In: Crystal RG WJ, Barnes PJ, Weibel ER, editor. The Lung: Scientific Foundations. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1997. p. 2205–18.

[11] Janoff A, Sloan B, Weinbaum G, Damiano V, Sandhaus RA, Elias J, et al. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. The American review of respiratory disease. 1977;115(3):461-78. Epub 1977/03/01.

[12] Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. The Journal of clinical investigation. 1988;82(6):1963-73. Epub 1988/12/01.

[13] Bode W, Meyer E, Jr., Powers JC. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochemistry. 1989;28(5):1951-63. Epub 1989/03/07.

[14] Owen CA, Campbell MA, Boukedes SS, Campbell EJ. Cytokines regulate membrane-bound leukocyte elastase on neutrophils: a novel mechanism for effector activity. The American journal of physiology. 1997;272(3 Pt 1):L385-93. Epub 1997/03/01.

[15] Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, et al. Structure and variation of human alpha 1-antitrypsin. Nature. 1982;298(5872):329-34. Epub 1982/07/22.

[16] Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O'Donnell E. The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry. 2001;40(51):15762-70. Epub 2001/12/19.

[17] Wiedow O, Luademann J, Utecht B. Elafin is a potent inhibitor of proteinase 3. Biochemical and biophysical research communications. 1991;174(1):6-10. Epub 1991/01/15.

[18] Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. The Journal of biological chemistry. 1990;265(25):14791-5. Epub 1990/09/05.
[19] Boudier C, Bieth JG. The proteinase: mucus proteinase inhibitor binding stoichiometry. The Journal of biological chemistry. 1992;267(7):4370-5. Epub 1992/03/05.

[20] Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(18):6692-6. Epub 1986/09/01.

[21] Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol. 2009;183(12):8148-56. Epub 2009/12/17.

[22] Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science. 1979;206(4424):1315-6. Epub 1979/12/14.

[23] Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proceedings of the National Academy of Sciences of the United States of America. 1982;79(6):2041-5. Epub 1982/03/01.

[24] Stone PJ, Calore JD, McGowan SE, Bernardo J, Snider GL, Franzblau C. Functional alpha 1-protease inhibitor in the lower respiratory tract of cigarette smokers is not decreased. Science. 1983;221(4616):1187-9. Epub 1983/09/16.

[25] Boudier C, Pelletier A, Pauli G, Bieth JG. The functional activity of alpha 1-proteinase inhibitor in bronchoalveolar lavage fluids from healthy human smokers and non-smokers. Clinica chimica acta; international journal of clinical chemistry. 1983;132(3):309-15. Epub 1983/08/31.

[26] Fera T, Abboud RT, Richter A, Johal SS. Acute effect of smoking on elastaslike esterase activity and immunologic neutrophil elastase levels in bronchoalveolar lavage fluid. The American review of respiratory disease. 1986;133(4):568-73. Epub 1986/04/01.

[27] Abboud RT, Fera T, Johal S, Richter A, Gibson N. Effect of smoking on plasma neutrophil elastase levels. The Journal of laboratory and clinical medicine. 1986;108(4):294-300. Epub 1986/10/01.

[28] Fujita J, Nelson NL, Daughton DM, Dobry CA, Spurzem JR, Irino S, et al. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. The American review of respiratory disease. 1990;142(1):57-62. Epub 1990/07/01.
[29] Vega-Carrascal I, Reeves EP, Niki T, Arikawa T, McNally P, O’Neill SJ, et al. Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J Immunol. 2011;186(5):2897-909. Epub 2011/01/26.

[30] Reeves EP, Williamson M, Byrne B, Bergin DA, Smith SG, Greally P, et al. IL-8 dictates glycosaminoglycan binding and stability of IL-18 in cystic fibrosis. J Immunol. 2010;184(3):1642-52. Epub 2009/12/23.

[31] Campbell EJ, White RR, Senior RM, Rodriguez RJ, Kuhn C. Receptor-mediated binding and internalization of leukocyte elastase by alveolar macrophages in vitro. The Journal of clinical investigation. 1979;64(3):824-33. Epub 1979/09/01.

[32] Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. American journal of respiratory and critical care medicine. 1999;159(6):1985-91. Epub 1999/06/03.

[33] Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, et al. Immunolocalization of elastase in human emphysematous lungs. The Journal of clinical investigation. 1986;78(2):482-93. Epub 1986/08/01.

[34] Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. The American review of respiratory disease. 1977;116(3):469-75. Epub 1977/09/01.

[35] Geraghty P, Rogan MP, Greene CM, Boxio RM, Poiriert T, O’Mahony M, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol. 2007;178(9):5871-8. Epub 2007/04/20.

[36] Geraghty P, Rogan MP, Greene CM, Brantly ML, O’Neill SJ, Taggart CC, et al. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro. Thorax. 2008;63(7):621-6. Epub 2008/02/06.

[37] Sommerhoff CP, Caughey GH, Finkbeiner WE, Lazarus SC, Basbaum CB, Nadel JA. Mast cell chymase. A potent secretagogue for airway gland serous cells. J Immunol. 1989;142(7):2450-6. Epub 1989/04/01.

[38] Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. The Journal of clinical investigation. 1990;85(3):682-9. Epub 1990/03/01.

[39] Takeyama K, Agusi C, Ueki I, Lausier J, Cardell LO, Nadel JA. Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules. The American journal of physiology. 1998;275(2 Pt 1):L294-302. Epub 1998/08/12.
[40] Fischer BM, Voynow JA. Neutrophil elastase induces MUC5AC gene expression in airway epithelium via a pathway involving reactive oxygen species. American journal of respiratory cell and molecular biology. 2002;26(4):447-52. Epub 2002/03/29.

[41] Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. The American journal of physiology. 1999;276(5 Pt 1):L835-43. Epub 1999/05/18.

[42] Amitani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. American journal of respiratory cell and molecular biology. 1991;4(1):26-32. Epub 1991/01/01.

[43] Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. The Journal of clinical investigation. 1992;89(5):1478-84. Epub 1992/05/01.

[44] Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS letters. 2003;544(1-3):129-32. Epub 2003/06/05.

[45] Leavell KJ, Peterson MW, Gross TJ. The role of fibrin degradation products in neutrophil recruitment to the lung. American journal of respiratory cell and molecular biology. 1996;14(1):53-60. Epub 1996/01/01.

[46] Banda MJ, Rice AG, Griffin GL, Senior RM. The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. The Journal of experimental medicine. 1988;167(5):1608-15. Epub 1988/05/01.

[47] Doring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol. 1995;154(9):4842-50. Epub 1995/05/01.

[48] Lee KY, Ho SC, Lin HC, Lin SM, Liu CY, Huang CD, et al. Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway. American journal of respiratory cell and molecular biology. 2006;35(4):407-14. Epub 2006/05/13.

[49] Yang JJ, Kettritz R, Falk RJ, Jennette JC, Gaido ML. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. The American journal of pathology. 1996;149(5):1617-26. Epub 1996/11/01.

[50] Nahori MA, Renesto P, Vargaftig BB, Chignard M. Activation and damage of cultured airway epithelial cells by human elastase and cathepsin G. European journal of pharmacology. 1992;228(4):213-8. Epub 1992/12/01.

[51] Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, et al. Elastase-mediated phosphatidylinerse receptor cleavage impairs apoptotic cell clear-
ance in cystic fibrosis and bronchiectasis. The Journal of clinical investigation. 2002;109(5):661-70. Epub 2002/03/06.

[52] Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol. 2000;165(6):3366-74. Epub 2000/09/07.

[53] Bergenfeldt M, Axelsson L, Ohlsson K. Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors. Scandinavian journal of clinical and laboratory investigation. 1992;52(8):823-9. Epub 1992/12/01.

[54] Duranton J, Bieth JG. Inhibition of proteinase 3 by [alpha] 1-antitrypsin in vitro predicts very fast inhibition in vivo. American journal of respiratory cell and molecular biology. 2003;29(1):57-61. Epub 2003/02/26.

[55] Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory leukocyte protease inhibitor with proteinase-3. American journal of respiratory cell and molecular biology. 1993;8(6):612-6. Epub 1993/06/01.

[56] Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2013;41(5):1042-50. Epub 2012/09/01.

[57] Ying QL, Simon SR. Elastolysis by proteinase 3 and its inhibition by alpha(1)-proteinase inhibitor: a mechanism for the incomplete inhibition of ongoing elastolysis. American journal of respiratory cell and molecular biology. 2002;26(3):356-61. Epub 2002/02/28.

[58] Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocyte cell line in the presence of activated neutrophils or purified proteinase 3. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(11):6261-6. Epub 1999/05/26.

[59] Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I, Canteloup S, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. American journal of respiratory cell and molecular biology. 1999;20(4):729-36. Epub 1999/04/01.

[60] Pendergraft WF, 3rd, Rudolph EH, Falk RJ, Jahn JE, Grimmler M, Hengst L, et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney international. 2004;65(1):75-84. Epub 2003/12/17.

[61] Takeyabu K, Betsuyaku T, Nishimura M, Yoshioka A, Tanino M, Miyamoto K, et al. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. The European respiratory journal : official journal of
the European Society for Clinical Respiratory Physiology. 1998;12(5):1033-9. Epub 1998/12/24.

[62] Lucey EC, Stone PJ, Breuer R, Christensen TG, Calore JD, Catanese A, et al. Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with in vitro observations on elastolysis by these enzymes. The American review of respiratory disease. 1985;132(2):362-6. Epub 1985/08/01.

[63] Takahashi H, Ishidoh K, Muno D, Ohwada A, Nukiwa T, Kominami E, et al. Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. The American review of respiratory disease. 1993;147(6 Pt 1):1562-8. Epub 1993/06/01.

[64] Reilly JJ, Jr., Chen P, Sailor LZ, Wilcox D, Mason RW, Chapman HA, Jr. Cigarette smoking induces an elastolytic cysteine proteinase in macrophages distinct from cathepsin L. The American journal of physiology. 1991;261(2 Pt 1):L41-8. Epub 1991/08/11.

[65] Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA, Jr., et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. The Journal of experimental medicine. 2000;192(11):1587-600. Epub 2000/12/06.

[66] Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ, Jr., et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. The Journal of clinical investigation. 2000;106(9):1081-93. Epub 2000/11/09.

[67] Bergsson G, Reeves EP, McNally P, Chotirmall SH, Greene CM, Greally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol. 2009;183(1):543-51. Epub 2009/06/23.

[68] Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB, Jr., O'Neill S, et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol. 2003;171(2):931-7. Epub 2003/07/09.

[69] Loffek S, Schilling O, Franzke CW. Series “matrix metalloproteinases in lung health and disease”: Biological role of matrix metalloproteinases: a critical balance. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2011;38(1):191-208. Epub 2010/12/24.

[70] Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. European journal of pharmacology. 2006;533(1-3):133-44. Epub 2006/02/21.
[71] Janoff A, Raju L, Dearing R. Levels of elastase activity in bronchoalveolar lavage fluids of healthy smokers and nonsmokers. The American review of respiratory disease. 1983;127(5):540-4. Epub 1983/05/01.

[72] Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. American journal of physiology Lung cellular and molecular physiology. 2002;283(4):L867-73. Epub 2002/09/13.

[73] Senior RM, Griffin GL, Mechem RP. Chemotactic activity of elastin-derived peptides. The Journal of clinical investigation. 1980;66(4):859-62. Epub 1980/10/01.

[74] Hunninghake GW, Davidson JM, Rennard S, Szapiel S, Gadek JE, Crystal RG. Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science. 1981;212(4497):925-7. Epub 1981/05/22.

[75] Nenan S, Planquois JM, Berna P, De Mendez I, Hitier S, Shapiro SD, et al. Analysis of the inflammatory response induced by rhMMP-12 catalytic domain instilled in mouse airways. International immunopharmacology. 2005;5(3):511-24. Epub 2005/02/03.

[76] Babusyte A, Stravinskaite K, Jeroch J, Lotvall J, Sakalauskas R, Sitkauskiene B. Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respiratory research. 2007;8:81. Epub 2007/11/16.

[77] Lavigne MC, Thakker P, Gunn J, Wong A, Miyashiro JS, Wasserman AM, et al. Human bronchial epithelial cells express and secrete MMP-12. Biochemical and biophysical research communications. 2004;324(2):534-46. Epub 2004/10/12.

[78] Xie S, Issa R, Sukkar MB, Oltmanns U, Bhavsar PK, Papi A, et al. Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cells. Respiratory research. 2005;6:148. Epub 2005/12/20.

[79] Churg A, Zhou S, Wright JL. Series “matrix metalloproteinases in lung health and disease”: Matrix metalloproteinases in COPD. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2012;39(1): 197-209. Epub 2011/09/17.

[80] Churg A, Wang X, Wang RD, Meixner SC, Pryzdial EL, Wright JL. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. American journal of respiratory cell and molecular biology. 2007;37(2): 144-51. Epub 2007/03/31.

[81] Raza SL, Nehring LC, Shapiro SD, Cornelius LA. Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. The Journal of biological chemistry. 2000;275(52):41243-50. Epub 2000/09/20.

[82] Botelho FM, Nikoa JK, Bauer C, Davis NH, Cohen ES, Anderson IK, et al. A mouse GM-CSF receptor antibody attenuates neutrophilia in mice exposed to cigarette
smoke. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2011;38(2):285-94. Epub 2011/03/26.

[83] Lavigne MC, Eppihimer MJ. Cigarette smoke condensate induces MMP-12 gene expression in airway-like epithelia. Biochemical and biophysical research communications. 2005;330(1):194-203. Epub 2005/03/23.

[84] Leclerc O, Lagente V, Planquois JM, Berthelier C, Artola M, Eichholtz T, et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2006;27(6):1102-9. Epub 2006/03/03.

[85] Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002-4. Epub 1997/09/26.

[86] Selman M, Cisneros-Lira J, Gaxiola M, Ramirez R, Kudlacz EM, Mitchell PG, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. Chest. 2003;123(5):1633-41. Epub 2003/05/13.

[87] Churg A, Wang RD, Tai H, Wang X, Xie C, Dai J, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. American journal of respiratory and critical care medicine. 2003;167(8):1083-9. Epub 2003/01/11.

[88] Le Quement C, Guenon I, Gillon JY, Lagente V, Boichot E. MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells. American journal of physiology Lung cellular and molecular physiology. 2008;294(6):L1076-84. Epub 2008/04/09.

[89] Vandebroucke RE, Dejonckheere E, Libert C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2011;38(5):1200-14. Epub 2011/06/11.

[90] Le Quement C, Guenon I, Gillon JY, Valenza S, Cayron-Elizondo V, Lagente V, et al. The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. British journal of pharmacology. 2008;154(6):1206-15. Epub 2008/05/22.

[91] Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. The American journal of pathology. 2003;163(6):2329-35. Epub 2003/11/25.

[92] Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM, et al. A distinctive alveolar macrophage activation state induced by cigarette smoking.
American journal of respiratory and critical care medicine. 2005;172(11):1383-92. Epub 2005/09/17.

[93] Wallace AM, Sandford AJ, English JC, Burkett KM, Li H, Finley RJ, et al. Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. Copd. 2008;5(1):13-23. Epub 2008/02/09.

[94] Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg M, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. American journal of respiratory and critical care medicine. 2001;163(3 Pt 1):786-91. Epub 2001/03/20.

[95] Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. American journal of respiratory and critical care medicine. 1997;156(1):240-7. Epub 1997/07/01.

[96] LaPan P, Brady J, Grierson C, Fleming M, Miller D, Sypek J, et al. Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum. BMC pulmonary medicine. 2010;10:40. Epub 2010/08/04.

[97] Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest. 2004;126(6):1802-10. Epub 2004/12/15.

[98] Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respiratory medicine. 2005;99(6):703-10. Epub 2005/05/10.

[99] Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. American journal of respiratory and critical care medicine. 1998;158(6):1945-50. Epub 1998/12/16.

[100] Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD. Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. Respiratory research. 2011;12:35. Epub 2011/03/25.

[101] Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respiratory medicine. 2003;97(6):634-9. Epub 2003/06/20.

[102] Minematsu N, Nakamura H, Tateno H, Nakajima T, Yamaguchi K. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochemical and biophysical research communications. 2001;289(1):116-9. Epub 2001/11/16.

[103] Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Ameri-
can journal of respiratory and critical care medicine. 2005;172(11):1378-82. Epub 2005/08/30.

[104] Zhou M, Huang SG, Wan HY, Li B, Deng WW, Li M. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chinese medical journal. 2004;117(10):1481-4. Epub 2004/10/23.

[105] Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. American journal of respiratory and critical care medicine. 2000;162(4 Pt 1):1355-60. Epub 2000/10/13.

[106] Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. American journal of respiratory cell and molecular biology. 2002;26(5):602-9. Epub 2002/04/24.

[107] Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Laboratory investigation; a journal of technical methods and pathology. 1998;78(9):1077-87. Epub 1998/10/06.

[108] Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117(3):684-94. Epub 2000/03/14.

[109] Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes & development. 2000;14(2):163-76. Epub 2000/02/01.

[110] Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. The Journal of biological chemistry. 2002;277(24):21352-60. Epub 2002/04/04.

[111] Ferry G, Lonchampt M, Pennel L, de Nanteuil G, Canet E, Tucker GC. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS letters. 1997;402(2-3):111-5. Epub 1997/02/03.

[112] Itoh Y, Nagase H. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. The Journal of biological chemistry. 1995;270(28):16518-21. Epub 1995/07/14.

[113] Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, et al. Epidermal growth factor system regulates mucin production in airways. Proceedings of the Na-
Deshmukh HS, Case LM, Wesselkamper SC, Borchers MT, Martin LD, Shertzer HG, et al. Metalloproteinases mediate mucin 5AC expression by epidermal growth factor receptor activation. American journal of respiratory and critical care medicine. 2005;171(4):305-14. Epub 2004/11/09.

D’Armiento J, Dalal SS, Okada Y, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 1992;71(6):955-61. Epub 1992/12/11.

Foronjy R, D’Armiento J. The role of collagenase in emphysema. Respiratory research. 2001;2(6):348-52. Epub 2001/12/12.

Finlay GA, Russell KJ, McMahon KJ, D’Arcy E M, Masterson JB, FitzGerald MX, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997;52(6):502-6. Epub 1997/06/01.

Elshaw SR, Henderson N, Knox AJ, Watson SA, Buttle DJ, Johnson SR. Matrix metalloproteinase expression and activity in human airway smooth muscle cells. British journal of pharmacology. 2004;142(8):1318-24. Epub 2004/07/22.

Mercer BA, Kolesnikova N, Sonett J, D’Armiento J. Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke. The Journal of biological chemistry. 2004;279(17):17690-6. Epub 2004/02/07.

Shiomi T, Okada Y, Foronjy R, Schiltz J, Jaenish R, Krane S, et al. Emphysematous changes are caused by degradation of type III collagen in transgenic mice expressing MMP-1. Experimental lung research. 2003;29(1):1-15. Epub 2003/03/26.

Selman M, Montano M, Ramos C, Vanda B, Becerril C, Delgado J, et al. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase. The American journal of physiology. 1996;271(5 Pt 1):L734-43. Epub 1996/11/01.

Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, et al. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. American journal of physiology Lung cellular and molecular physiology. 2008;294(6):L1149-57. Epub 2008/04/15.

Ramos C, Cisneros J, Gonzalez-Avila G, Becerril C, Ruiz V, Montano M. Increase of matrix metalloproteinases in woodsmoke-induced lung emphysema in guinea pigs. Inhalation toxicology. 2009;21(2):119-32. Epub 2008/10/07.

Gosselink JV, Hayashi S, Elliott WM, Xing L, Chan B, Yang L, et al. Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary
disease. American journal of respiratory and critical care medicine. 2010;181(12):1329-35. Epub 2010/01/16.

[125] Ilumets H, Rytila PH, Sovijarvi AR, Tervahartiala T, Myllarniemi M, Sorsa TA, et al. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scandinavian journal of clinical and laboratory investigation. 2008;68(7):618-23. Epub 2008/01/01.

[126] Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax. 2007;62(8):706-13. Epub 2007/02/22.

[127] Lee EJ, In KH, Kim JH, Lee SY, Shin C, Shim JJ, et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest. 2009;135(2):344-52. Epub 2008/08/30.

[128] American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900. Epub 2003/10/03.

[129] Turino GM, Barker AF, Brantly ML, Cohen AB, Connelly RP, Crystal RG, et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1718-25. Epub 1996/12/01.

[130] Jones EA, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med. 1978;55(2):139-48. Epub 1978/08/01.

[131] Abboud RT, Ford GT, Chapman KR. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J. 2001;8(2):81-8. Epub 2001/04/26.

[132] Mordwinkin NM, Louie SG. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert Opin Pharmacother. 2007;8(15):2609-14. Epub 2007/10/13.

[133] Stocks JM, Brantly M, Pollock D, Barker A, Kueppers F, Strange C, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD. 2006;3(1):17-23. Epub 2006/12/21.

[134] Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 1997;10(10):2260-3. Epub 1997/12/05.

[135] Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737-44. Epub 2001/03/13.
COPD Clinical Perspectives

[136] Carter RI, Mumford RA, Treonze KM, Finke PE, Davies P, Si Q, et al. The fibrinogen cleavage product Aalpha-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax. 2011;66(8):686-91. Epub 2011/05/28.

[137] Gottlieb DJ, Luisetti M, Stone PJ, Allegra L, Cantey-Kiser JM, Grassi C, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med. 2000;162(6):2069-72. Epub 2000/12/09.

[138] Campos MA, Alazemi S, Zhang G, Wanner A, Salathe M, Baier H, et al. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med. 2009;103(10):1532-9. Epub 2009/05/26.

[139] Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480-5. Epub 2000/11/18.

[140] Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. American journal of respiratory and critical care medicine. 1999;160(5 Pt 1):1468-72. Epub 1999/11/11.

[141] Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2009;33(6):1345-53. Epub 2009/02/07.

[142] Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055-62. Epub 1987/04/23.

[143] Russi EW. Alpha-1 antitrypsin: now available, but do we need it? Swiss Med Wkly. 2008;138(13-14):191-6. Epub 2008/04/05.

[144] McCarthy C, Dimitrov BD. Augmentation therapy for alpha-1 antitrypsin deficiency--not enough evidence to support its use yet! Copd. 2010;7(3):234; author reply 5-6. Epub 2010/05/22.

[145] Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax. 2002;57(8):709-14. Epub 2002/08/01.

[146] Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991;88(3):891-7. Epub 1991/09/01.

[147] Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494-8. Epub 2002/06/05.
[148] Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, et al. Alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120(12):4236-50. Epub 2010/11/10.

[149] Stoller JK, Rouhani F, Brantly M, Shahin S, Dweik RA, Stocks JM, et al. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest. 2002;122(1):66-74. Epub 2002/07/13.

[150] group TA--adrs. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158(1):49-59. Epub 1998/07/09.

[151] Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443-52. Epub 2010/01/08.

[152] Stone PJ, Morris TA, 3rd, Franzblau C, Snider GL. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans. Respiration. 1995;62(2):76-9. Epub 1995/01/01.

[153] Ma S, Lin YY, He J, Rouhani FN, Brantly M, Turino GM. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. Copd. 2013;10(4):473-81. Epub 2013/04/09.

[154] Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Danish medical bulletin. 2010;57(9):A4175. Epub 2010/09/08.

[155] McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997;111(2):394-403. Epub 1997/02/01.

[156] Campos MA, Kueppers F, Stocks JM, Strange C, Chen J, Griffin R, et al. Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK). COPD. 2013. Epub 2013/07/19.

[157] Schriber EE, Davidson JM, Sutcliffe MC, Swindell BB, Bernard GR. Comparison of elastin peptide concentrations in body fluids from healthy volunteers, smokers, and patients with chronic obstructive pulmonary disease. The American review of respiratory disease. 1992;145(4 Pt 1):762-6. Epub 1992/04/01.

[158] Viglio S, Iadarola P, Lupi A, Trisolini R, Tinelli C, Balbi B, et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2000;15(6):1039-45. Epub 2000/07/08.
[159] Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax. 2006;61(12):1037-42. Epub 2006/06/14.

[160] Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4):822-32. Epub 2006/04/06.

[161] Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax. 2007;62(8):657-60. Epub 2007/08/10.

[162] Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136. Epub 2010/10/06.

[163] Wanner A, Arce AD, Pardee E. Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD. 2012;9(6):583-8. Epub 2012/12/05.

[164] Cantin AM, Woods DE, Cloutier D, Dufour EK, Leduc R. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. American journal of respiratory cell and molecular biology. 2002;27(6):659-65. Epub 2002/11/22.

[165] Kwon KS, Song M, Yu MH. Purification and characterization of alpha 1-antitrypsin secreted by recombinant yeast Saccharomyces diastaticus. J Biotechnol. 1995;42(3):191-5. Epub 1995/10/16.

[166] Kang HA, Nam SW, Kwon KS, Chung BH, Yu MH. High-level secretion of human alpha 1-antitrypsin from Saccharomyces cerevisiae using inulinase signal sequence. J Biotechnol. 1996;48(1-2):15-24. Epub 1996/07/18.

[167] Sandoval C, Curtis H, Congote LF. Enhanced proliferative effects of a baculovirus-produced fusion protein of insulin-like growth factor and alpha(1)-proteinase inhibitor and improved anti-elastase activity of the inhibitor with glutamate at position 351. Protein engineering. 2002;15(5):413-8. Epub 2002/05/30.

[168] Lindhout T, Iqbal U, Willis LM, Reid AN, Li J, Liu X, et al. Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes. Proc Natl Acad Sci U S A. 2011;108(18):7397-402. Epub 2011/04/20.

[169] Blanchard V, Liu X, Eigel S, Kaup M, Rieck S, Janciauskiene S, et al. N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line. Biotechnol Bioeng. 2011;108(9):2118-28. Epub 2011/04/16.

[170] Ross D, Brown T, Harper R, Pamarthi M, Nixon J, Bromirski J, et al. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells. J Biotechnol. 2012;162(2-3):262-73. Epub 2012/10/06.
[171] Wang Z, Hilder TL, van der Drift K, Sloan J, Wee K. Structural characterization of recombinant alpha-1-antitrypsin expressed in a human cell line. Anal Biochem. 2013;437(1):20-8. Epub 2013/03/07.

[172] Massoud M, Bischoff R, Dalemans W, Pointu H, Attal J, Schultz H, et al. Expression of active recombinant human alpha 1-antitrypsin in transgenic rabbits. J Biotechnol. 1991;18(3):193-203. Epub 1991/05/01.

[173] Archibald AL, McClenaghan M, Hornsey V, Simons JP, Clark AJ. High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic mice. Proc Natl Acad Sci U S A. 1990;87(13):5178-82. Epub 1990/07/01.

[174] Wright G, Carver A, Cottom D, Reeves D, Scott A, Simons P, et al. High level expression of active human alpha 1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y). 1991;9(9):830-4. Epub 1991/09/01.

[175] Spencer LT, Humphries JE, Brantly ML. Antibody response to aerosolized transgenic human alpha1-antitrypsin. The New England journal of medicine. 2005;352(19):2030-1. Epub 2005/05/13.

[176] Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. The Journal of clinical investigation. 1989;84(4):1349-54. Epub 1989/10/01.

[177] McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991;337(8738):392-4. Epub 1991/02/16.

[178] Berger M, Sorensen RU, Tosi MF, Dearborn DG, Doring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest. 1989;84(4):1302-13. Epub 1989/10/01.

[179] Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nature medicine. 2007;13(12):1423-30. Epub 2007/12/07.

[180] Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. The Journal of clinical investigation. 1989;84(4):1145-54. Epub 1989/10/01.

[181] Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2007;29(2):240-50. Epub 2006/10/20.
[182] Schalkwijk J, Chang A, Janssen P, De Jongh GJ, Mier PD. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol. 1990;122(5):631-41. Epub 1990/05/01.

[183] Alkemade JA, Molhuizen HO, Ponec M, Kempenaar JA, Zeeuwen PL, de Jongh GJ, et al. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci. 1994;107 (Pt 8):2335-42. Epub 1994/08/01.

[184] van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, et al. Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol. 2000;278(1):L51-8. Epub 2000/01/25.

[185] Marischen L, Wesch D, Schroder JM, Wiedow O, Kabelitz D. Human gammadelta T cells produce the protease inhibitor and antimicrobial peptide elafin. Scand J Immunol. 2009;70(6):547-52. Epub 2009/11/13.

[186] Mihaila A, Tremblay GM. Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z Naturforsch C. 2001;56(3-4):291-7. Epub 2001/05/24.

[187] Sallenave JM, Si Tahar M, Cox G, Chignard M, Gauldie J. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol. 1997;61(6):695-702. Epub 1997/06/01.

[188] Guyot N, Zani ML, Maurel MC, Dallet-Choisy S, Moreau T. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry. 2005;44(47):15610-8. Epub 2005/11/23.

[189] Guyot N, Zani ML, Berger P, Dallet-Choisy S, Moreau T. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Biol Chem. 2005;386(4):391-9. Epub 2005/05/19.

[190] Carter RI, Ungurs MJ, Mumford RA, Stockley RA. Alapha-Val360: a marker of neutrophil elastase and COPD disease activity. Eur Respir J. 2013;41(1):31-8. Epub 2012/04/24.

[191] Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994;11(6):733-41. Epub 1994/12/01.

[192] Reid PT, Marsden ME, Cunningham GA, Haslett C, Sallenave JM. Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett. 1999;457(1):33-7. Epub 1999/09/16.

[193] Simpson AJ, Cunningham GA, Porteous DJ, Haslett C, Sallenave JM. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum Gene Ther. 2001;12(11):1395-406. Epub 2001/08/04.
[194] Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun. 2003;71(7):3766-74. Epub 2003/06/24.

[195] Vachon E, Bourbonnais Y, Bingle CD, Rowe SJ, Janelle MF, Tremblay GM. Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol Chem. 2002;383(7-8):1249-56. Epub 2002/11/20.

[196] Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371-85. Epub 2008/11/04.

[197] Wilkinson TS, Dhaliwal K, Hamilton TW, Lipka AF, Farrell L, Davidson DJ, et al. Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am J Pathol. 2009;174(4):1338-46. Epub 2009/03/07.

[198] Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem. 2006;281(46):34730-5. Epub 2006/09/19.

[199] Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, et al. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol. 2004;172(7):4535-44. Epub 2004/03/23.

[200] Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett. 1999;452(3):309-13. Epub 1999/07/01.

[201] Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond). 2006;110(1):21-35. Epub 2005/12/13.

[202] Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J. 2008;275(9):2008-20. Epub 2008/03/18.

[203] Simpson AJ, Wallace WA, Marsden ME, Govan JR, Porteous DJ, Haslett C, et al. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol. 2001;167(3):1778-86. Epub 2001/07/24.

[204] McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM. The antimicrobial antiprotease elafin binds to lipopolysaccharide and modulates macrophage responses. Am J Respir Cell Mol Biol. 2005;32(5):443-52. Epub 2005/01/26.

[205] Nobar SM, Zani ML, Boudier C, Moreau T, Bieth JG. Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3. FEBS J. 2005;272(22):5883-93. Epub 2005/11/11.
[206] Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL, et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem. 2008;283(47):32377-85. Epub 2008/09/19.

[207] D’Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. PLoS One. 2013;8(2):e56352. Epub 2013/02/27.

[208] Guyot N, Bergsson G, Butler MW, Greene CM, Weldon S, Kessler E, et al. Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases. Biol Chem. 2010;391(6):705-16. Epub 2010/04/08.

[209] Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73(3):1271-4. Epub 2005/02/26.

[210] Ding A, Yu H, Yang J, Shi S, Ehrt S. Induction of macrophage-derived SLPI by Mycobacterium tuberculosis depends on TLR2 but not MyD88. Immunology. 2005;116(3):381-9. Epub 2005/10/21.

[211] Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88(3):417-26. Epub 1997/02/07.

[212] Wen J, Nikitakis NG, Chaisuparat R, Greenwell-Wild T, Gliozzi M, Jin W, et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol. 2011;178(6):2866-78. Epub 2011/06/07.

[213] Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest. 1997;99(5):894-900. Epub 1997/03/01.

[214] Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology. 2012;17(6):1006-12. Epub 2012/05/18.

[215] Yang J, Zhu J, Sun D, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta. 2005;1745(3):310-7. Epub 2005/08/23.

[216] Geraghty P, Greene CM, O’Mahony M, O’Neill SJ, Taggart CC, McElvaney NG. Secretory leukocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem. 2007;282(46):33389-95. Epub 2007/09/20.
[217] Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med. 2005;202(12):1659-68. Epub 2005/12/15.

[218] Reeves EP, Ryan D, McElvaney OJ, Bergin DA, Pohl K, Molloy K, Alsaleh K, Aljorfi A, Kandalaft O, O’Flynn E, Geraghty P, O’Neill SJ, McElvaney NG. Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5 triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease. BioMed Research International. 2013.

[219] Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun. 1996;64(11):4520-4. Epub 1996/11/01.

[220] Wiedow O, Harder J, Bartels J, Streit V, Christophers E. Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun. 1998;248(3):904-9. Epub 1998/08/15.

[221] Tomee JF, Hiemstra PS, Heinzel-Wieland R, Kauffman HF. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J Infect Dis. 1997;176(3):740-7. Epub 1997/09/18.

[222] Vogelmeier C, Buhl R, Hoyt RF, Wilson E, Fells GA, Hubbard RC, et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol. 1990;69(5):1843-8. Epub 1990/11/01.

[223] McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90(4):1296-301. Epub 1992/10/01.

[224] Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994;150(1):207-13. Epub 1994/07/01.

[225] Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O’Neill SJ, Levine RL, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001;276(36):33345-52. Epub 2001/07/04.

[226] Gibbons AM, McElvaney NG, Taggart CC, Cryan SA. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul. 2009;26(6):513-22. Epub 2008/10/18.

[227] Ramadas RA, Wu L, LeVine AM. Surfactant protein A enhances production of secretory leukoprotease inhibitor and protects it from cleavage by matrix metalloproteinases. J Immunol. 2009;182(3):1560-7. Epub 2009/01/22.
[228] Ju CR, Xia XZ, Chen RC. Expressions of tumor necrosis factor-converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease. Chin Med J (Engl). 2007;120(17):1505-10. Epub 2007/10/03.

[229] Lockett AD, Kimani S, Ddungu G, Wrenger S, Tuder RM, Janciauskiene SM, et al. alpha(1)-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-alpha. Am J Respir Cell Mol Biol. 2013;49(1):143-50. Epub 2013/03/26.

[230] Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Yoshikawa S, Sugimotoa K. Pretreatment of sivelestat sodium hydrate improves the lung microcirculation and alveolar damage in lipopolysaccharide-induced acute lung inflammation in hamsters. Shock. 2006;26(1):95-8. Epub 2006/06/20.

[231] Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol. 2001;69(2):241-7. Epub 2001/03/29.

[232] Yasui S, Nagai A, Aoshiba K, Ozawa Y, Kakuta Y, Konno K. A specific neutrophil elastase inhibitor (ONO-5046.Na) attenuates LPS-induced acute lung inflammation in the hamster. Eur Respir J. 1995;8(8):1293-9. Epub 1995/08/01.

[233] Song JS, Kang CM, Rhee CK, Yoon HK, Kim YK, Moon HS, et al. Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 2009;35(10):817-29. Epub 2009/12/10.

[234] Abe T, Usui A, Oshima H, Akita T, Ueda Y. A pilot randomized study of the neutrophil elastase inhibitor, Sivelestat, in patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg. 2009;9(2):236-40. Epub 2009/05/19.

[235] Miyoshi S, Hamada H, Ito R, Katayama H, Irifune K, Suwaki T, et al. Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis. Drug Des Devel Ther. 2013;7:305-16. Epub 2013/04/19.

[236] Tsuboko Y, Takeda S, Mi S, Nakazato K, Tanaka K, Uchida E, et al. Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis. Drug Des Devel Ther. 2012;6:273-8. Epub 2012/10/24.

[237] Lucas SD, Costa E, Guedes RC, Moreira R. Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev. 2013;33 Suppl 1:E73-101. Epub 2011/06/18.

[238] Luisetti M, Piccioni PD, Doninni M, Peona V, Pozzi E, Grassi C. Studies of MR 889, a new synthetic proteinase inhibitor. Biochem Biophys Res Commun. 1989;165(2):568-73. Epub 1989/12/15.

[239] Luisetti M, Sturani C, Sella D, Madonini E, Galavotti V, Bruno G, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J. 1996;9(7):1482-6. Epub 1996/07/01.
Churg A, Wang RD, Xie C, Wright JL. alpha-1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2003;168(2):199-207. Epub 2003/04/12.

Wright JL, Farmer SG, Churg A. A neutrophil elastase inhibitor reduces cigarette smoke-induced remodelling of lung vessels. Eur Respir J. 2003;22(1):77-81. Epub 2003/07/29.

Shinguh Y, Yamazaki A, Inamura N, Fujie K, Okamoto M, Nakahara K, et al. Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor. Eur J Pharmacol. 1998;345(3):299-308. Epub 1998/05/20.

Numanami H, Koyama S, Nelson DK, Hoyt JC, Freels JL, Habib MP, et al. Serine protease inhibitors modulate smoke-induced chemokine release from human lung fibroblasts. Am J Respir Cell Mol Biol. 2003;29(5):613-9. Epub 2003/05/10.

Stevens T, Ekholm K, Granse M, Lindahl M, Kozma V, Jungar C, et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther. 2011;339(1):313-20. Epub 2011/07/28.

Vogelmeier C, Aquino TO, O’Brien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD. 2012;9(2):111-20. Epub 2012/03/31.

Stockley R, De Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013;107(4):524-33. Epub 2013/02/26.

Mocchegiani E, Giacconi R, Costarelli L. Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: genetic factors and treatment implications. Curr Opin Pulm Med. 2011;17 Suppl 1:S11-9. Epub 2012/01/11.

Magnussen H, Watz H, Kirsten A, Wang M, Wray H, Samuelsson V, et al. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. Pulm Pharmacol Ther. 2011;24(5):563-70. Epub 2011/06/01.

Dahl R, Titlestad I, Lindqvist A, Wielders P, Wray H, Wang M, et al. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther. 2012;25(2):169-77. Epub 2012/02/07.

Wu Y, Li J, Wu J, Morgan P, Xu X, Rancati F, et al. Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 2012;22(1):138-43. Epub 2011/12/14.

Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, et al. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary
disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d] furan-3-sulfonamido)-3-methylbutanoic acid (MMP408). J Med Chem. 2009;52(7):1799-802. Epub 2009/03/13.

[252] Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001;81(8):1119-31. Epub 2001/08/15.

[253] Morris A, Kinnear G, Wan WY, Wyss D, Bahra P, Stevenson CS. Comparison of cigarette smoke-induced acute inflammation in multiple strains of mice and the effect of a matrix metalloproteinase inhibitor on these responses. J Pharmacol Exp Ther. 2008;327(3):851-62. Epub 2008/09/23.

[254] Pemberton PA, Cantwell JS, Kim KM, Sundin DJ, Kobayashi D, Fink JB, et al. An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse. COPD. 2005;2(3):303-10. Epub 2006/12/07.

[255] Gross NJ. Novel antiinflammatory therapies for COPD. Chest. 2012;142(5):1300-7. Epub 2012/11/08.

[256] Attucci S, Gauthier A, Korkmaz B, Delepine P, Martino MF, Saudubray F, et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther. 2006;318(2):803-9. Epub 2006/04/22.

[257] Delacourt C, Herigault S, Delclaux C, Poncin A, Levame M, Harf A, et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol. 2002;26(3):290-7. Epub 2002/02/28.

[258] Honore S, Attalah HL, Azoulay E, Soussy CJ, Saudubray F, Harf A, et al. Beneficial effect of an inhibitor of leukocyte elastase (EPI-hNE-4) in presence of repeated lung injuries. Shock. 2004;22(2):131-6. Epub 2004/07/17.

[259] Zani ML, Baranger K, Guyot N, Dallet-Choisy S, Moreau T. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Sci. 2009;18(3):579-94. Epub 2009/02/26.

[260] Tanga A, Saidi A, Jourdan ML, Dallet-Choisy S, Zani ML, Moreau T. Protection of lung epithelial cells from protease-mediated injury by trappin-2 A62L, an engineered inhibitor of neutrophil serine proteases. Biochem Pharmacol. 2012;83(12):1663-73. Epub 2012/04/03.